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Abstract
Background: Seeking direct patient input to inform health care decision making is vital to
maintain and improve quality of life among those with chronic diseases. The initiative to
incorporate and understand patient-reported outcomes (PROs) in clinical practice has recently
increased in the field of ophthalmology to improve glaucoma management.
Objective: To identify the most important predictor variables for four PROs: social support and
community integration, presence of depressive symptoms, vision-related quality of life (VRQoL)
and preference-based Health-Related quality of life (HRQoL).
Methods: A cross-sectional study was conducted among glaucoma and glaucoma suspect
patients in London, Ontario (n = 250). Data were collected through medical chart reviews and
face-to-face interviews. The four PROs were measured using validated tools. Linear, logistic and
stepwise regression models, and classification and regression trees were built using candidate
variables. Through leave-one-out cross-validation, the predictive performance of each model was
assessed with mean absolute error, standard error and standard deviation.
Results: Use of mobility aids, best corrected visual acuity (BCVA), income and living
arrangements were common predictor variables identified for VRQoL, and social support and
community integration. Use of mobility aids was also identified for the presence of depressive
symptoms, and BCVA for preference-based HRQoL.
Conclusion: The identified predictor variables suggest that routinely collected variables in
ophthalmic practice alone are not sufficient to understand PROs. Our research study presents
evidence that may allow better management of glaucoma through guidance of how to integrate
patient-centered approach to care with the traditional clinical approach.

Keywords
Glaucoma, patient-reported outcome, social support, community integration, depressive
symptoms, vision-related quality of life, preference-based health-related quality of life
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Chapter 1

1

Introduction

Glaucoma is a disease of the nerve that connects the eye to the brain. It is the most common
cause of irreversible blindness worldwide and its cause remains unknown1. In 2002, glaucoma
accounted for about 12.3% of the 37 million people who were blind world-wide2. Vision loss is
the most frequently feared disability for Canadians and has one of the highest direct health care
costs3. Globally, the direct cost of vision loss in 2010 was $2.3 trillion4. In the United States, it
was estimated that 17.8%, of the direct costs from ocular diseases, was due to patients with
glaucoma2. In 2007, the financial burden of vision loss in Canada was estimated to be $15.8
billion and by 2032, vision loss is expected to cost Canadians about $30.3 billion 3.
Public spending on healthcare is one of the largest government expenditures and health care
costs continue to escalate, especially with the elderly Canadian population expected to represent
about 25% of the population by 20365. Given the cost constraints, policy decisions to deliver
quality health care, optimal clinical practice and a patient-centered health care system must be
supported by evidence that incorporates patient-reported outcomes (PROs)6. The diagnosis and
progression of glaucoma is accompanied by negative consequences on health outcomes directly
affecting the patient7. Thus, in addition to clinical characteristics of glaucoma, expanded
elements of health care such as the economic burden, patient characteristics and PROs also need
to be measured for glaucoma management.
Although glaucoma cannot be cured, the progression can be delayed with treatment. Glaucoma
impacts the patient in various ways, such as psychological effects, functional disabilities,
treatment side effects, treatment costs, and inconvenience of treatments8. In today’s healthcare
climate, patients with glaucoma need to be managed efficiently in a comprehensive manner,
rather than a limited scope determined solely by the clinical symptoms of the eye. Quaranta et al.
(2016) presented a review of the quality of life (QoL) literature in glaucoma, which suggested
that patients with glaucoma may be at a higher risk for a lower QoL, including the burden from
side effects and costs of treatment9. Since, glaucoma is a multifactorial disease and requires
multidimensional management, understanding the factors associated with different QoL domains
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is necessary for developing effective interventions10. Current treatment options for glaucoma
include topical and oral ophthalmic medications, laser and incisional surgical treatments, all
which focus on prevention of disease progression by reducing intraocular pressure (IOP)9. Some
patients may not require initiation of treatment upon first assessment, but rather may be routinely
observed until the risk of progression is sufficient to warrant intervention. The primary goal is to
preserve the patients’ QoL by preventing functional visual impairment and minimizing the side
effects and complications of glaucoma treatment9. Thus, analyzing the relationship between
clinical characteristics, individual characteristics and various QoL domains will provide a more
comprehensive understanding of the patient to assist with glaucoma management. Glaucoma
management entails more than just the correct diagnosis of the disease, because it requires
lifelong treatment and assessment11. To effectively treat and manage the patient, a
comprehensive understanding of the patient is required. This will allow for patients to be more
involved in their care, understand the disease progression, improve their overall health and
reduce avoidable health care costs11.
In ophthalmic practice, disease management outcomes have been mainly assessed with clinical
characteristics as opposed to PRO measures12. Over the recent years, the need to understand the
fundamental disease processes, appreciate individual differences, preserve high level of visual
function while improving the quality of care has enticed tremendous interest in studying PROs
among glaucoma patients9,13–18. PROs are fundamental to involving patients in their clinical
decision-making process and understanding patient experiences, as we move from a “diseasebased” to “patient-centered” model of care12,13. This is especially important in chronic diseases
that require compliance to lifelong management. Linking clinical and demographic variables to
PROs is important for understanding the associations between variables within a complex
construct such as Health-Related quality of life (HRQoL). Understanding this association is
important to describe the patient’s experiences in response to their disease management and
treatment. Overall, it is an improved method of assessing the patients’ health status19. Thus, in
addition to expert opinions and review of relevant literature, this thesis presents the adaptation of
a model that conceptualizes the associations of clinical variables to HRQoL measures, proposed
by Wilson and Cleary in 1995 (Figures 2-1 and 2-2)19.
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Improving health among glaucoma patients starts with understanding health outcomes as
perceived by the patient (i.e., PROs). The importance has recently increased due to the creation
of formalized programs by governments which seek direct patient input into health care decision
making policies – Food and Drug Administration (FDA) and Centers of Excellence in
Regulatory Science and Innovation (CERSI) project20, and Ontario Clinical Expert Panel for the
Glaucoma Quality Standard (May 2017). While the need to integrate PROs in glaucoma
management and treatment is apparent, it is routinely not used by ophthalmologists21. The
“Canadian Ophthalmological Society evidence-based clinical practice guidelines for the
management of glaucoma in the adult eye” does not specify the PRO instruments available, thus
ophthalmologists may not be aware of which instruments are relevant to their patients 22. There
are several instruments available to assess PROs, therefore determining which one to use among
glaucoma patients can be a challenge.
Developing a predictive model for PROs may improve clinical decision-making by providing
guidance as to how to incorporate PROs in ophthalmic practice and identifying the need for
additional support and/or resources. Machine learning techniques are used to automatically
detect patterns from a given dataset and in the clinical decision-making process23. Previous
studies of glaucoma have not performed machine learning techniques to identify which variables
are predictive of PROs. The first step to building a predictive model, is to identify important
clinical and demographic variables that are strongly associated with a specific PRO. This is the
goal of our research study. The identified clinical and demographic variables will be used to
build a predictive model aimed to estimate PROs. The developed model can be used to identify
patients at risk of poor PROs and determine clinical interventions as per the patients’ needs. This
resulting predictive model will further need to be assessed for accuracy in various populations in
order to be used as a validated tool. The predictive model can also be beneficial for research
purposes, as it will allow researchers, health economists, policy makers and health care
administrators to efficiently estimate PROs at a population level to provide evidence to guide
administrators on health budget allocation for chronic diseases such as glaucoma.
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Chapter 2

2

Literature Review

2.1 Background of Glaucoma
Population based studies identified glaucoma as the main cause of irreversible world-wide
blindness24. Glaucoma is a chronic neuro-degenerative disorder of the optic nerve that is
characterized by progressive structural and functional loss, resulting in vision loss and
blindness24,25. It is characterized by the degeneration of retinal ganglion cells and their axons,
which results in visual impairment and optic nerve damage 26. Retinal ganglion cells receive
visual information and the optic nerve is responsible for carrying the visual information from the
eye to the brain26. Retinal ganglion cell death and optic nerve fiber loss are among the most
important changes that characterize the glaucoma diagnosis27. Initial changes to the optic nerve
are asymptomatic28.
Glaucoma is detected through a comprehensive eye examination that includes assessment of the
status of the optic nerve and retina, measurement of the best corrected visual acuity (BCVA) at
various distances, intraocular pressure (IOP), central corneal thickness (CCT), visual field and
assessment of the anatomical angle between the cornea and iris29. Some of the major risk factors
for glaucoma that have been identified include: elevated IOP, increased cup-to-disc ratio (CDR),
decreased CCT, pseudoexfoliation syndrome, genetic factors and older age24. IOP is the only
currently known treatable risk factor, which is reduced using medication, laser and/or traditional
surgery30. There are also potential risk factors that remain unidentified.
In a healthy eye, constant eye pressure is maintained, whereas in an eye with glaucoma the
damage occurs when fluid builds up and increases the pressure in the eye31. There is a subset of
patients who experience glaucomatous optic neuropathy at normal IOPs which further highlights
the complexity of the disease and likely contributes to the fact that the etiology remains
unknown32. Glaucoma patients begin losing their peripheral vision which progresses to central
visual loss followed by blindness if left untreated. Most glaucoma diagnoses are based on
progressive structural and functional optic nerve damage; however there is currently no
definitive standard for diagnosis31. Since glaucoma is not curable and is irreversible, the goal of

5

glaucoma management and treatment is to minimize its progression and to preserve the patients’
HRQoL. Glaucoma treatment starts with establishing the type of glaucoma diagnosis33.

2.2 Types of Glaucoma
There are several types of glaucoma that have been identified based on etiology of the
underlying disease and mechanism of abnormality in the eye. The two main types of glaucoma
include open-angle and angle-closure.
Primary Open-angle glaucoma (POAG) is the most common type of glaucoma
characterized by a functional blockage of the drainage canal34,35. Because of the
blockage, fluid accumulates and causes increased pressure in the eye and damage to the
optic nerve.
Angle-closure glaucoma (ACG) requires immediate medical attention when it occurs
acutely, because the entrance to the drainage canal becomes anatomically very narrow or
completely closed35. Thus, the pressure can rise rapidly and cause extreme pain to the
patient and sudden vision loss.
Normal tension glaucoma (NTG) is a type of glaucoma in which the optic nerve is
damaged without increased pressure in the eye34. It is unclear as to why the optic nerve is
susceptible to damage, even when the eye pressure is relatively normal.
Secondary glaucoma develops secondary to other conditions such as diabetes, eye
trauma or inflammation in the eye, in which the additional factor causes elevated IOP34.
The most common types of secondary glaucoma include: pseudoexfoliative glaucoma,
pigmentary glaucoma and neovascular glaucoma.
Glaucoma suspects are patients who have some, but not all, of the featured
characteristics of glaucoma. Glaucoma suspects may have normal pressure in the eye, but
their optic nerve or visual field findings suggest a risk of developing glaucoma34. In some
cases, patients may have elevated eye pressure (ocular hypertension) but show no signs of
optical nerve damage. Patients with ocular hypertension are at greater risk for developing
glaucoma compared to age-matched normal subjects34. Glaucoma suspects can be those
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that have risk factors for future development of glaucoma or those who suffer early
glaucoma damage that cannot be differentiated from normal damage due to aging36.
Depending upon the extent of the risk factor profile, glaucoma suspects may or may not
receive treatment.

2.3 Epidemiology of Glaucoma
2.3.1 Prevalence of Glaucoma
Most of the epidemiological studies in glaucoma pertain specifically to POAG, because most
studies were conducted in North America and Europe, where the most common form of
glaucoma is POAG37. Several studies have attempted to determine the prevalence of glaucoma
since the 1920s, however the criteria for diagnosing glaucoma have changed since then and
continue to evolve, the latter primarily based on advancements in diagnostic technologies38–40. It
was not until 1938, when gonioscopy was introduced, that open-angle and closed-angle
glaucoma were differentiated and glaucoma was not merely based upon the elevation of IOP38.
Glaucoma is the second leading causes of global blindness and the leading cause of irreversible
visual loss that disproportionately affects people residing in Asia and Africa2,41. In 2010, it was
estimated that about 60.5 million people globally were affected by glaucoma and this number is
expected to increase to 79.6 million by 2020 and 111.8 million by 204041,42. Data from
population based studies reported the mean prevalence for POAG worldwide in 2010 as 1.96%
and 59.1% of all people with glaucoma were female42. Although there have been a number of
prevalence surveys conducted in various racial and ethnic groups worldwide, caution must be
taken in interpreting these results as there exists great variability in the methodology, quality of
the data collected and variability among glaucoma diagnostic criteria43.
POAG is the most common form of glaucoma, accounting for about 19% of all blindness among
African Americans compared to only 6% of Caucasians44. Africans have a higher prevalence of
POAG than do Europeans or Asians, and ACG is most common in Asians38,43. African
Americans are 15 times more likely to be visually impaired and six to eight times more likely to
be blind from glaucoma than Caucasians45. In a systematic review and meta-analysis that
included population-based studies published up until March 2013, the global prevalence of
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glaucoma was reported to be 3.54% for a population between 40 to 80 years of age41. Prevalence
increases proportionally with age. Those older than 70 years of age have an “average estimated
prevalence of 6% in white populations, 16% in black populations and 3% in Asian
populations”38. Thus, glaucoma is of great concern due to the current aging population. It is also
important to note that the rate of undiagnosed glaucoma is fairly high, since glaucoma is often
asymptomatic until the very advanced stage at which point irreversible functional blindness is
likely41.
Population based studies for determining disease prevalence are crucial, since there exist
regional differences in the prevalence of different types of glaucoma46. However, such studies
are minimal in Canada. In 1965, a screening survey of about 18,000 participants conducted in
Scarborough, Ontario reported a glaucoma prevalence of 2.2%47. Analysis of self-reported data
in 2002 to 2003, revealed that about 409 000 Canadians were diagnosed with glaucoma, of
which 2.7% were above 40 years old and 11% were above 80 years old26. Then in 2005, another
screening study on a high-risk population reported glaucoma in 7.2% of the participants49. In
2007, based on Canada-wide health surveys, the prevalence of self-reported glaucoma was 2.7%
among Canadians older than 40 years of age50. Further, in a 2008-2009 cross-sectional study
conducted in Toronto, Ontario consisting of Canadians 50 years of age or older, reported 7.5% of
the participants having glaucoma and the prevalence of undetected glaucoma was 3.9%50. It is
estimated that about 50% of people with glaucoma are not aware that they have the disease and
therefore are not receiving glaucoma treatment51. Since glaucoma is relatively asymptomatic in
the early stages, the statistics obtained from health surveys are likely underestimated.

2.3.2

Incidence of Glaucoma

Very few incidence studies of glaucoma have been reported. Since POAG is initially an
asymptomatic disease, patients may not seek treatment until the later stages. Effective screening
for glaucoma continues to be a global health problem52. In the earlier stages, it can be
challenging to identify the precise stage at which a glaucoma suspect progresses to glaucoma.
Difficulties with staging the glaucoma diagnosis and the need to follow up with patients is a
challenge in determining the incidence of glaucoma37.
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The first reliable data were collected in a 1989 longitudinal study, in Sweden, among a
population of 55 to 69 years of age, which reported the estimated incidence rate to be 0.25% in a
10 year follow-up period 28. In a more recent study the four-year incidence of POAG in Barbados
was reported to be 2.2%, and incidence rates increased from 1.2% at 40 to 49 years of age to
4.2% at 70 years or greater38. Among people in Netherlands, the rates increased from 1% at age
60 to 3% at age 8038. The incidence rate over time in a Caucasian population increased from 0.08
at 40 years of age to 1.46 at 80 years of age37. Thus, the incidence of glaucoma increases with
age.

2.3.3

Risk Factors for Developing Glaucoma

When assessing the risk factors for a disease, large population-based studies are more
representative than hospital-based studies, due to the selection bias among hospital patients,
which can lead to an overestimation of certain potential risk factors for developing glaucoma37.
The main risk factors that have been examined in population-based studies include: demographic
factors such as age, gender and race; ocular factors such as IOP, appearance of the optic nerve,
myopia, hypermetropia, presence of exfoliation, pigment dispersion, inflammation, narrow
angles and history of trauma; systemic factors such as diabetes, hypertension and vasospastic
disorder; genetic factors and other proposed lifestyle risk factors such as cigarette smoking and
alcohol intake37.

2.4

Glaucoma Treatment and Management

There is always a trade-off involved when making treatment decisions. In the case of glaucoma
treatment, patients make a treatment decision based on the trade-off between avoidance of
blindness and treatment side effects and complications53. Understanding HRQoL in glaucoma
patients could provide insight into the extent of visual disability and side effects of the treatments
from the perspective of the patient9. It is both ideal and important to consider the patient’s
perspective and their priorities when developing a treatment plan27. This is further punctuated by
the fact that glaucoma management has been plagued by well documented poor patient
compliance to medical therapy11,54,55. Since glaucoma is a progressive disease and is incurable,
understanding how glaucoma affects PROs can influence medical decision making to optimize
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treatment strategies and adherence, develop rehabilitation programs, allocate necessary resources
and ultimately improve patient-physician relationships7.
Glaucoma treatments include medications, laser and surgical interventions, which can influence
the patient’s HRQoL, by relieving symptoms but also by inducing side-effects and
complications. As POAG tends to be asymptomatic in the early to moderate stages, patients often
perceive the treatments as being more negative than the disease itself. In a cross-sectional study
among POAG and ocular hypertension (OHT) patients, in addition to clinical characteristics,
medication side effects and glaucoma surgery also affected HRQoL56. Commonly reported side
effects from topical and systemic medications include burning, tearing, blurred vision, stinging
and redness57. In addition, the complexity of treatment regimen; taking multiple doses; having to
travel with the medications; and difficulties in administering medications can negatively
influence HRQoL57–59. In a cross-sectional study, the results showed that difficulty with the use
of medication was the only factor that was negatively associated with HRQoL scores59. Other
studies have indicated that the greater number of doses per day and use of additional medications
correlated with noncompliance57,59,60. The daily use of medication may stress the burden of
having an incurable disease and interfere with their daily life. Patients who are satisfied with
their treatment have a greater adherence to their treatment, more likely to be involved in their
care and use resources appropriately58,59. Thygesen et al. (2008) reported that the treatment with
greater cost savings was found in the social care sector (i.e., assistance with daily activities) as
opposed to the health care sector (i.e., medical treatment)61. Majority of the costs in terms of
glaucoma management were found to be medication-related, with the financial burden increasing
with advanced glaucoma severity62.
The Collaborative Initial Glaucoma Treatment Study (CIGTS) randomized newly diagnosed
POAG patients to treatment with medications or trabeculectomy. Although there were very few
between-group differences in outcomes, patients in the trabeculectomy group reported more
difficulties with visual acuity related activities58. After the five-year follow-up period, patients
reported a reduction of symptom frequency and burden in both treatment groups58. A crosssectional study with Brazilian glaucoma patients found that surgery was a predictor of poor
HRQoL scores in patients only with early stage glaucoma60. A cross-sectional study
investigating the HRQoL among three groups: medical treatment, surgical treatment and
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combination of medical and surgical treatment found no difference between the HRQoL scores
among patients in the surgical or medical group60. The results also suggest that in the surgical
group, glaucoma had less of an impact on their daily lives, although patients were still concerned
about the progression of glaucoma60.
Glaucoma is a chronic disease that affects many aspects of a patient’s life; thus, success of
glaucoma management should not be measured only by objective clinical parameters such as
IOP. This is a key factor when considering the goal of the various therapies. For example, a low
risk surgical intervention that reduces the dependency on medications may be far more beneficial
to a patient’s QoL without any additional effects on IOP reduction. Many patients with glaucoma
are combating other concurrent comorbidities requiring treatment that could influence their
compliance and satisfaction.
Optimal treatment and management should incorporate objective measures of the patient’s visual
function and glaucoma severity, as well as the subjective measure of the likely PROs under
different possible treatment options63. In terms of a cost-effective treatment, the goal is to
achieve a better health outcome at a lower cost. Thus, understanding the impact of glaucoma,
identifying individual needs and assessing the effectiveness of treatment options is crucial to
glaucoma management.

2.5

Health Outcomes of Glaucoma

Traditionally, health outcomes were based on a biomedical model and objectively defined as
mortality and morbidity associated with biological functioning13. This approach does not
consider the patients’ perception and experiences of their current health state. More recently,
health outcomes are being viewed in terms of a biopsychosocial model, which incorporates a
more holistic view of the patient and includes psychological and social factors64. Health
outcomes discussed in our research study include clinical outcomes and PROs.

2.5.1 Clinical Outcomes
Clinical outcomes are outcomes that are not reported by the patient and are used by clinicians to
diagnose and manage the progression of the disease13. There is great variability in the clinical
presentation of patients with glaucoma27. Clinical outcomes are identified through a
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comprehensive eye exam which include the following assessments: best corrected visual acuity
(BCVA), gonioscopy, tonometry, corneal pachymetry, perimetry, visual acuity test and optic
nerve and retinal nerve fiber layer imaging 65. All components of the eye exam are used to
diagnosis and determine the staging of glaucoma (Section 4.4.2.5 defines the stages of
glaucoma). Clinical outcomes vary depending on the type and severity of glaucoma30.

2.5.1.1

Gonioscopy

Gonioscopy is a technique used to assess the configuration of the anterior segment angle. This is
located between the cornea and the iris66. Goinioscopy permits the determination of whether the
angle is anatomically open or closed66.

2.5.1.2

Tonometry

Tonometry measures the IOP using a tonometer27. Although, elevated IOP levels is a prominent
clinical presentation that is strongly associated with the development of glaucoma, there are
patients with elevated IOP levels (> 21 mm Hg) that do not develop glaucoma and other patients
who are diagnosed with glaucoma who have a normal IOP level (£ 21 mm Hg)26,67.

2.5.1.3

Corneal Pachymetry

Pachymetry determines the corneal thickness. Normal CCT ranges between 545 and 550 µm and
is race dependent66. Thin corneas (< 500 µm) are a risk factor for progression of glaucoma, while
thicker corneas (> 600 µm) are relatively protective30.

2.5.1.4

Perimetry

A perimetric test, also known as visual field test, is used to quantify the level and rate of
functional visual impairment and is complemented by image-based structural measurements of
the optic disc, retinal nerve fiber layer and ganglion cells68. Visual field loss is a sign of
glaucomatous damage and is a crucial measurement for management of the disease68. Mean
deviation (MD) is the overall deviation from normal values (0 dB to -2 dB) of the hill of vision
which defines the visual field69.
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Glaucoma at a later stage is generally more straightforward to diagnosis; however for glaucoma
suspects, who present with normal visual field and elevated IOP, they usually require repeat
perimetric tests over time68. With patients already diagnosed with glaucoma, perimetric tests play
a key role in managing the disease to determine if the treatment is adequate or if a change is
required68.

2.5.1.5

Visual Acuity Test

The Snellen chart is an eye chart typically used to measure central visual acuity, which is a
measure of how well a patient sees at various distances (i.e., sharpness of vision)27. Visual acuity
is scored as a set of two numbers known as the Snellen fraction70. For example, usually 20/20 is
defined as normal, where the top number represents the distance from which the test is conducted
and the bottom number represents the distance that the typical healthy eye can see the letters on a
certain line of the eye chart70. The loss or abnormality of visual functions leads to visual
impairment71.

2.5.1.6

Optic Nerve and Retinal Nerve Fiber Layer Imaging

Dilated eye examination is performed to examine the optic nerve and retina for signs of
damage66. Specifically, the imaging tests used are Heidelberg Retinal Tomography (HRT), which
provides a quantitative evaluation of the topography of the optic nerve and/or Optical Coherence
Tomography (OCT) which measures the retinal nerve fiber thickness within the retina72.
Optic nerve damage produces thinning and decreased visibility of the retinal fiber layer (RNFL)
35

. Due to the way the retinal ganglion cells enter the optic nerve, the vertical cup-to-disc ratio is

a useful clinical measurement of the structural status of the optic nerve30. Typically, glaucoma is
associated with a progressively increasing cup-to-disc ratio, due to the degeneration of the retinal
ganglion cells30. Normal cup-to-disc ratio is about 0.3 (ranging between 0.1 and 0.8)67.

2.5.2 Symptoms
Symptoms are associated with the disease itself and the treatment effect73. Glaucoma progression
can be asymptomatic in the early to moderate stages of the open angle disease27. Elevated IOP
usually raises concern about the risk of glaucoma69. Pain is experienced by the patient when IOP
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rises rapidly69. Visual impairment is the most noticeable symptom of glaucoma, but this is
typically not experienced by the patient until the later stages of the disease69. Glaucoma usually
develops slowly with very minimal initial symptoms; however, in some patients the rate of loss
can be relatively rapid, depending upon several factors including the stage of the disease at the
time of diagnosis74. Thus, it is important to routinely examine glaucoma suspects on a regular
basis66. A key point is that the damage is irreversible with no known treatments once it has
occurred.

2.5.3 Patient-Reported Outcomes
Clinical characteristics such as visual field and IOP are predominately the main outcomes
assessed for clinical and research purposes despite neither defining the disease. As these are not
able to provide information on the well-being and experiences of the patient, there is a need to
focus on assessing PROs. Patients with glaucoma experience visual impairment, activity
limitations, side effects of treatment, as well as effects on general health, lifestyle and emotional
well-being. In addition to the medical problem, these patients experience social, economic and
psychological problems. Thus, multidisciplinary approaches to research are needed to understand
the biological, psychological and sociological factors influencing health-related outcomes as
perceived by the patient. Understanding how glaucoma affects the patients’ daily activities as
well as obtaining a perspective on the effects of disease progression and treatment are important
in a patient-centered comprehensive approach to glaucoma management.
PROs are needed to assess health outcomes from the patients’ perspective. PROs are able to
address the patients’ vision-specific functional loss affecting different domains of their life and
overall satisfaction of the patient’s health state23. PROs are subjective measures reflecting patient
experiences, perceptions, symptoms, functional status or other domains influencing HRQoL, in
terms of their health condition75. PROs represent what is important to the patient as it relates to
the management and treatment of the disease75. Hence, PROs can help improve patient
knowledge, identify issues and provide insights that influence glaucoma management76.
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2.5.3.1

Quality of Life and Health-Related Quality of Life

QoL and HRQoL are generic health outcome measures, which are often used interchangeably.
Although QoL and HRQoL capture the subjective health perception of the patient, they each
provide different information77. QoL is defined as a broad concept which encompasses all
aspects of life such as family circumstances, finance, living arrangement and job satisfaction77.
QoL is defined in the context of the patients’ culture and values76. On the other hand, HRQoL is
a component of QoL that is focused on the individuals’ perspective of their own health state as it
relates to their overall functioning and well-being in terms of physical function, social and
psychological factors77. HRQoL is usually a measure of self-perceived health status, depicting
how health affects QoL or the utility associated with different health states77.
Although the ocular damage due to glaucoma is initially asymptomatic, the patients’ HRQoL can
be affected as soon as the diagnosis is made and/or the early damage and its treatment cause
effects other than diminished central acuity. One of the very first studies to understand HRQoL
in glaucoma patients in 1997, found that visual function impairment was correlated with
peripheral vision, distance activities and vision-specific dependency78. Research across different
HRQoL domains is important in order to provide insight to the aspects of daily living that are
negatively affected by glaucoma76. Poor HRQoL in glaucoma patients can be due to various
reasons and can differ across various patient populations. Reasons for diminished HRQoL
specifically among glaucoma patients include: stress of diagnosis, disease severity, functional
loss due to vision loss, loss of independence, inconvenience of frequent treatment and its side
effects, cost of treatment and regular appointments for monitoring the progression of glaucoma62.
Literature supports that even the mere diagnosis of glaucoma can negatively affect HRQoL79.
Glaucoma is a progressive disease, but the diagnosis of glaucoma can come as a surprise to many
patients, since patients may attribute their vision loss to normal degradation with aging29. It is
often shocking to patients that they already have moderate to advanced disease at the time of
diagnosis80,81. Current literature suggests HRQoL is more affected by the way patients perceive
their vision as opposed to the objective measurement of it9.
Patients diagnosed with POAG reported lower HRQoL scores than patients with suspected
glaucoma9. Another study which used the same HRQoL measure, but with a larger proportion of
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patients with early stage glaucoma, reported that HRQoL scores were not greatly affected by
visual acuity or visual function impairment9. Past studies also suggest that HRQoL scores tend to
be worse in patients with more advanced stages of glaucoma and with concurrent
comorbidities9,82. In a cross-sectional study among POAG and OHT patients, the clinical
characteristics that affected HRQoL were MD and visual acuity56. The findings also suggest a
stronger impact of visual function loss in the better eye on HRQoL than visual function loss in
the worse eye9,56. Evidence in the literature suggests that the worst HRQoL is associated with
more severe glaucoma, however there still exists some evidence of worst HRQoL even in the
early stages of glaucoma17. Generally, HRQoL scores are associated with visual function loss,
visual acuity and number of years since glaucoma diagnosis9. Despite the variability in study
methodology, several studies have reported significant relationships between visual impairment
and HRQoL9,83.

2.5.3.2

Functional Status and Well-being

Health effects of glaucoma extend beyond the eye, as patients with glaucoma experience
limitations to their functional status and well-being84,85. Clinical outcomes such as visual field
and visual acuity loss, can limit the patients’ ability to be independent, productive, participate in
society, perform daily activities, and impact social and emotional well-being85. Assessing
functional status and well-being is important to inform rehabilitation care9.
The World Health Organization (WHO) refers to disability as a broad term encompassing
impairments, activity limitations and participation restrictions86. Patients with disabilities, such
as visual impairment, require coordination of care among a multidisciplinary care team (i.e.,
optometrists, ophthalmologists, social workers and rehabilitation services). ‘Functional status’
and ‘health status’ are among other terms used in a similar context as QoL and HRQoL13. Health
status is usually referred to the broader well-being of the patients in terms of disability54.
Functional status assess the ability of the individual to perform social roles without any
limitations and focuses on tasks such as activities of daily living77.
Performing activities of daily living is often a problem in patients with visual impairment85,87.
Visual impairment and progression to blindness, increases functional disability, dependency,
accidents, depression, decline in physical and mental health9,76,87,88. Patients with bilateral visual
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field loss have reported poor performance on mobility activities such as driving, in comparison
to patients with unilateral visual field loss89. Progression of glaucoma can lead to vision-related
disability, loss of visual acuity and blindness, thus patients experience problems associated with
activities of daily living such as reading and driving24. Visually impaired individuals are at a
higher risk for accidents, social withdrawal and depression9. Due to the loss of visual acuity in
glaucoma patients, many report concern with activities requiring central and near vision and
outdoor mobility9. Activities such as walking, reading, visibility at night and noticing objects
through peripheral vision, have been reported to be major concerns45. Patients with moderate to
severe visual field loss, decreased contrast sensitivity and depth perception, report difficulties
with driving and the need to discontinue or drive less frequently9. Tasks requiring central or near
vision, outdoor mobility and driving are the most deteriorated activities of daily living among
glaucoma patients76. Outdoor mobility restrictions was strongly correlated with the amount of
visual field loss in the worse eye and those with visual impairment were more likely to report
accidents and falls76. Such limitations to activities of daily living can lead to patients’ loss of
independence and lower HRQoL. Glaucoma patients with moderate to severe visual field loss
perform poorly on activities related to functional independence and level of mobility90.
Glaucoma is a chronic condition that potentially can cause blindness91. Patients with glaucoma
have reported high prevalence of anxiety and depression17. Driving limitations, fear of falling
and imbalance also contribute to the relationship between glaucoma and depression17. In a casecontrol study, anxiety and depression in POAG patients was reported to be significantly higher
than the reference group92. In addition, increase in age and visual field loss were associated with
depression92. Symptoms of depression were not found to be correlated with poor visual function;
however, it was significantly correlated with the patient’s perception of their vision92.
Glaucoma impacts a patient’s everyday functional abilities and each patient copes with the
disease differently85. Understanding how glaucoma impacts the patient’s functional status and
well-being, can assist with developing better management strategies for patients with glaucoma.

2.6

Patient-Reported Outcome Instruments

PRO instruments measure the patient’s health status such as HRQoL6. They are often selfreported by the patient, but can also be completed by a proxy if the patient cannot self-report.
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Assessing PROs to better manage the patient can be difficult using only one instrument, since
patient tailored care requires a multidimensional understanding: personal factors, social
relationships and participation, psychological well-being, physical health and health condition73.
Although PROs are considered an important aspect of the patient’s health management and is
collected in a standardized method in certain clinical practices, they are rarely collected in
ophthalmic practice due to possible reasons such as: determining which PRO measure to use;
lack of guidance on how to implement PRO measures routinely; difficulties with interpreting the
results; time constraints; and resource limitations63,73,93. Currently, there is a priority to
incorporate the collection of PROs in ophthalmic practice, and a group of ophthalmology experts
in Ontario are making an effort with government professionals to implement PRO assessment in
routine practice –Ontario Clinical Expert Panel for the Glaucoma Quality Standard, 2017. Types
of developed PRO instruments include: generic, disease-specific, dimension-specific and utility
measures88.
Among patients with glaucoma or at risk of glaucoma, previous studies assessed PROs using
generic, glaucoma-specific, vision-specific, medication-specific and utility instruments95–97.
These studies often used a combination of one generic and one vision-specific instrument. Our
research study uses four different PRO instruments. There is a need for clear recommendations
and guidance in clinical utilization of PRO instruments, given the plethora of PRO instruments
available.

2.6.1 Generic Instruments
Generic tools were developed to provide the overall impact of the health condition and can be
compared across various health conditions and are used to measure the general functional status
of the patient 98. Among generic instruments such as: EuroQol-5D (EQ-5D), the Sickness
Impact Profile (SIP) and World Health Organization Quality of Life (WHOQOL), the most
common generic tool used in glaucoma research is the Medical Outcomes Study Short Form-36
(SF-36)17.
The main advantage with the generic tool is that it can be used to compare across various
populations, including populations without the health condition of interest13. These instruments
provide a summary score across various dimensions such as physical and social functioning,

18

emotional and physical problems, role limitations and mental health13. However, because generic
instruments assess broad dimensions, they may not be as directly relevant to specific populations
and are potentially less responsive to clinically important changes13. Studies using the generic
instrument found that patients with glaucoma reported lower scores across all domains,
compared to patients without glaucoma85,99.

2.6.2 Glaucoma - Specific Instruments
Glaucoma-specific instruments focus on the specific disease and reflects issues that are important
to patients with glaucoma97. They are usually used to detect changes in the same population over
time97. Glaucoma-specific tools assess the symptoms, functional impairment, vision-related
factors and extent to which glaucoma and treatment interfere with their health state94. They are
clinically relevant, specific to the disease, but are rarely used in clinic, rather are mainly used as
a research tool94. Overall, disease-specific instruments are more relevant and sensitive than
generic instruments with regards to capturing changes in health status due to glaucoma
management and treatment94.

2.6.3 Vision - Specific Instruments
Vision-specific instruments measure the functional impairment among patients with ocular
conditions. They focus on visual ability, specific task performance and impact of visual
impairment on the patient and their daily acitivites98. Commonly used vision-specific instruments
include: the Visual Function Index (VF-14), National Eye Institute Visual Function
Questionnaire (NEI VFQ), Activities of Daily Visual Scale (ADVS) and Visual Activities
Questionnaire (VAQ)98. Vision-specific instruments were reported to be more sensitive than
generic instruments when comparing patient with glaucoma to a reference group46,72,73. They
were also found to be more correlated with clinical assessments46,72,73.

2.6.4 Dimension - Specific Instruments
Dimension-specific instruments are not popularly used in glaucoma research, thus their
appropriateness as an outcome measure needs to be carefully considered and data on their
psychometric properties are limited. Dimension-specific instruments are used when there is an
interest in assessing a specific domain (i.e., social and emotional well-being). It is often more
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detailed than the generic and disease-specific instruments13. Dimension-specific instruments
discussed in this project include the Community Integration Questionnaire (CIQ) and the Patient
Health Questionnaire - 9 (PHQ-9).

2.6.5 Utility Measures
Utility measures provide information on the patient’s preferences and values as it relates to their
current health state13. Generally used techniques to obtain direct health utility values include:
rating scales, standard gamble and time trade-off13. Utility values are useful for economic
evaluations such as cost-utility analysis13.

2.7

Selected Patient-Reported Outcomes

Selection of appropriate PRO instruments depends on the purpose of the study and requires
careful consideration of methodological issues such as: validity, reliability, feasibility and
generalizability6,94. Several PRO tools in glaucoma have been developed to assess aspects of
HRQoL. However, the challenge is deciding which of the many measurement tools to use. It is a
constant battle to choose a tool that is responsive and relevant to clinical outcomes, and is
concise and easy to administer6. The responsiveness of the instrument is an important
consideration, because the instrument may fail to detect a change which can result in falsenegatives75. The reliability and validity of these measurement tools are assessed using
psychometric properties100.
Vandenbroeck et al. (2011) conducted a systematic review to identify glaucoma-specific and
vision-related functional status, disease specific, treatment specific, and overall QoL tools, based
on FDA guidelines63. Vision-specific tools are useful to clinicians and are specific to the disease
progression and treatments94. The disease-specific tools do not capture the multi-dimensional
concept that QoL entails58.
Selecting an instrument to measure PROs depends on the objectives and population under
investigation97. Based on the literature, time constraints, ease of use, professional judgement,
relevance to the study population and study outcomes, the following four PROs were assessed in
our research study: social support and community integration as measured by the Community
Integration Questionnaire (CIQ); depressive symptoms as measured by the Patient Health
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Questionanire-9 (PHQ-9), vision-related quality of life (VRQoL) as measured by the National
Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25); and preference based HRQoL as
measured by the Time Trade-Off (TTO) technique.

2.7.1 Social Support and Community Integration
More people are living with disabilities and therefore, there needs to be an emphasis on the
inclusion of social well-being to assist patients in rehabilitative strategies. Among patients with
visual impairment, functional activities and participation in household, social and occupational
activities are important outcome measures101.
Previous literature identified that an essential component of functional independence and
accessibility is being able to drive, and vision-related diseases may prevent individuals from
driving. It has been found that individuals with visual impairment have a decrease in functional
independence, since they are prevented from performing activities such as driving102. Since
glaucoma is a disease that causes visual impairment, it influences the patients’ driving abilities,
and it has been shown that non-drivers have poorer community integration than drivers103. Thus,
it is important to be aware of these patients’ social support and level of community integration,
as this can provide support for better tailored interventions. In many other chronic disease
populations, such tailored interventions support improvements in QoL104.
Among other chronic disease populations, social support and community integration has been
shown to affect mortality and predict self-reported disease outcomes104. Although, there are
many instruments available to assess functional abilities, not many assess community integration
as a multidimensional concept. The 32-item Craig Handicap Assessment and Reporting
Technique (CHART) is the most commonly used measure of integration; however, the CIQ is
more comprehensible, brief and easy to administer, with good measurement properties (refer to
Section 4.5.1 for a detailed description of the CIQ)105.
The CIQ was originally developed by an expert panel with experience in various aspects of
rehabilitation and research for individuals with traumatic brain injury to assess changes in social
functioning106,107. It focuses on behavioural states rather than emotional states. It consists of three
domains that are consistent with the WHO definition of disability: home integration, social
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integration and productive activity101. Some items measure the frequency of activities performed
and other items measure the degree to which assistance is required to perform activities101. The
International Classification of Functioning, Disability and Health (ICF) framework consists of a
functioning and disability domain that includes activity and participation, which coincides with
the CIQ items. The CIQ score ranges from 0 to 29 (greater social support and community
integration). Previous studies among brain trauma patients reported that age, sex and level of
education to have an effect on CIQ scores and females scored higher in the home integration
domain whereas males scored higher in the productive activity domain108. Previous studies using
the CIQ that were comparable to our study population, were conducted among geriatric patients
and patients with physical disabilities101,109.
Overall, the CIQ is interpretable and feasible in assessing the level of social support and
community integration. With diseases that result in some form of disability, it is important to
consider outcome measures related to social functioning to evaluate quality of care and need for
care beyond medical treatment such as rehabilitation care coordination. Although, the CIQ has
not been used in patients with ocular diseases such as glaucoma, vision loss is debilitating, thus it
is important to consider the social integration of such individuals. Functional activity and
participation are important outcomes across all diseases. The CIQ is generally applicable to
patients with a disability and has been used in a heterogeneous sample of adult patients with
disabilities101.

2.7.2 Depressive Symptoms
Vision loss can negatively influence the emotional well-being of individuals78. More
specifically, vision loss is associated with an increased risk of depression110. Among glaucoma
patients, depression can arise due to fear of potential blindness, burden of treatments and
impairments of activities of daily living16. There is the well-known social stigma around mental
illnesses and ophthalmologists may not be aware of such conditions when treating their patients.
There also exists a relationship between QoL and depression16. Tastan et al. (2010) found QoL to
be negatively associated with depression in Turkish patients with glaucoma111. Depression can
also results in disability and loss of productivity112. Thus, measuring depressive symptoms may
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be relevant to the care of patients with glaucoma and other ocular diseases, to provide these
patients with the necessary support and resources.
Lim et al. (2016) reported mild to severe depressive symptoms among 30% of glaucoma patients
in Singapore, using the Hamilton Depression Rating Scale (HAM-D)16. Lim et al. (2016) also
found variables such as sex, race, clinical characteristics and average NEI VFQ-25 scores were
significantly associated with depressive symptoms16. Further, Skalicky et al. (2008) determined
that among their study population, depression prevalence increased with glaucoma severity,
using the Geriatric Depression Scale-15113.
The PHQ-9 was developed as a diagnostic tool for depression. It is one of the most common
validated tools used to measure depression in research to identify depressive symptoms. It
measures the severity of depression into five categories: none, mild, moderate, moderately severe
and severe. It is a rapid assessment tool and it scores each of the nine “Diagnostic and Statistical
Manual of Mental Disorders, 4th edition” (DSM-IV) criteria. It is a brief standardized valid tool
for assessing depressive symptoms. The PHQ-9 was found to support diagnosis made by
clinicians and other screening instruments such as the Beck Depression and Anxiety Inventories
and the Center for Epidemiologic Studies Depression Scale114. Previous research concluding the
PHQ-9 as an adequate tool for diagnosing depressive disorders have been conducted in primary
care settings114.
To date, the PHQ-9 was not used in patients with ocular diseases such as glaucoma. Generally,
as the PHQ-9 depression severity increased, there was a decrease in functional status, increase in
health utilization and decrease in work productivity115. Typically, measures of depression have
been assessed as part of a larger measurement tool consisting of a broad array of domains, such
as the Short Form health survey. However, for our research study, the PHQ-9 was used to
capture the specific dimension of emotional well-being.

2.7.3 Vision-related Health-Related Quality of Life
The most widely used instrument in vision-related functioning is the NEI VFQ-25. It was
designed specifically for a clinical setting and consists of 12 domains: general health, general
vision, visual pain, near activities, distance activities, social functioning, mental health, role
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difficulties, dependency, driving, colour vision and peripheral vision76. It was developed to
measure vision-specific functioning and impact of vision problems on HRQoL for various ocular
conditions. Both the 51-item and the shorter 25-item version questionnaires were widely used in
different groups of patients and shown to be internally consistent, reproducible and responsive in
glaucoma patients9. Vision-specific instruments were found to be more sensitive and relevant to
glaucoma than generic QoL instruments, as it contains items regarding activities of daily living,
social functioning and coping related to vision loss57. The NEI VFQ-25 scores have a closer
relationship to clinical outcomes, in comparison to generic instruments 95 .
In the Early Manifest Glaucoma Trial, newly diagnosed glaucoma patients were randomized to
receive treatment or no initial treatment. Patients scored a high mean composite score of 88.8 out
of 100 on the NEI VFQ-25 scale116. Although early treatment significantly reduced clinical
outcomes of glaucoma progression, it did not affect VRQoL scores116. In addition, the NEI
VFQ-25 scores were correlated with low visual acuity in the better-seeing eye, worse MD and
lens opacities, but no correlation was found with age, sex, IOP, cardiovascular disease or
systemic hypertension116. In the Los Angeles Latino Eye Study, a correlation was observed
between visual field loss and NEI VFQ-25 subscale scores117. Findings from previous studies
suggest that glaucoma patients with visual field loss report lower VRQoL scores9,76,117. In
addition, previous studies found the composite NEI VFQ-25 scores of patients with glaucoma to
be lower, and lower scores were correlated with more severe visual field defects118.
As opposed to a generic or glaucoma-specific instrument, a vision-specific instrument was
selected for our research study. Patients with glaucoma may present with other concurrent ocular
conditions as well, thus our research study included patients diagnosed with various ocular
conditions, including glaucoma and glaucoma suspects. A glaucoma-specific instrument would
have been too limited and a generic instrument would have been too broad. Hence, a visionspecific instrument was determined to be valid for our study population.

2.7.4 Preference-Based Health-Related Quality of Life
Although non-preference-based measures are useful in identifying declines in visual function,
they do not assess how the patient’s visual function influences their daily life119. Thus, it is

24

necessary to assess the patients’ perception of their own health state. Preference-based HRQoL
outcomes use utility values to present the preference values of the patient.
The two most common methods of assessing utility values are the TTO and standard gamble
(SG) methods. The TTO technique s a tool used in health economics to help determine HRQoL
of patients, where the patient trades the length of life for QoL. In ophthalmology, the utility
value is calculated by dividing the number of years a patient is willing to trade for perfect vision
by the numbers of years expected to live, subtracted by 1.0120. Utility values are rated on scale
between death (utility = 0.0) and perfect health (utility = 1.0). On the other hand, with the SG
method, the patient is presented with a theoretical treatment and two possible outcomes
(treatment works or does not work)120. Patients are then asked the percent chance of blindness
they are willing to risk before refusing the treatment120. The percentage obtained is then
subtracted from 1.0 to obtain the SG utility value, which describes how undesirable the patient
perceives their present health state (i.e., the more risk the patient is willing to tolerate, the less
desirable they perceive their health state)120. The TTO technique is easier to administer than the
SG method119.
Utility values were previously used to measure preference-based HRQoL among glaucoma
patients. Total visual acuity, visual acuity in the better eye and comorbidity significantly affect
utility scores9. A study of glaucoma and glaucoma suspect patients, reported on average high
TTO utility values of 0.93 and 0.98 respectively (22% glaucoma and 11% glaucoma suspect
patients were willing to trade some years of their remaining life expectancy for perfect
vision)119,121. On the other hand, a study of Indian glaucoma patients reported on average a low
TTO utility value of 0.64, representing a poorer preference-based HRQoL96. Gupta et al., (2005)
found significant associations between TTO utility values and the degree of visual acuity loss
and educational status96. The utility values were found to be poorly correlated with visual field.
Patients who were blind reported a lower average utility value of 0.67, meaning that they were
willing to trade more years for perfect vision. Bass et al. (1997) assessed the utility value of
patients prior to cataract surgery, and found that TTO utility values were closely related to
feelings of depression and difficulties with social interactions more so than clinical meausres122.
Brown et al. (1999) found that visual loss is associated with a decrease in the patients’
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preference-based HRQoL, in which patients with a poor visual acuity value (i.e., counting
fingers) were willing to give up more years of their remaining life compared to patients with a
better visual acuity (i.e., 20/20)123. A study of Chinese patients reported a mean utility value of
0.88, suggesting that most were not willing to trade their remaining years for perfect vision124.
Aspinall et al. (2008) reported that only 17% of the patients were willing to consider trading their
remaining years of life for perfect vision125.
The TTO technique is a preference-based measure that assesses the subjective impact of diseases
on HRQoL and provides information for economic evaluation. It overcomes the limitation of
many questionnaires that provide a composite measure, by using preference-based choices to
provide a numerical value representing the patients HRQoL120. Although utility measures lack
precision, unlike other HRQoL measures, they allow for comparison across various disease
states119. Hence, the TTO technique was used for our research study.

2.8 Linking Clinical Variables with Patient-Reported Outcomes
Health outcomes are influenced by clinical factors, characteristics of the individual and
environmental factors (i.e., healthcare facility, social support system). Several different PRO
measures are used, which makes it difficult to compare results across studies126. In addition to
literature review and expert opinions, the Wilson and Cleary (1995) model was adapted to
identify variables and outcome measures for our research study.
The Wilson and Cleary (1995) model incorporates biological, social and psychological domains
to present the relationships among measures of patient outcomes (Figure 2-1)19. The model
illustrates that all components lead to an overall HRQoL as the endpoint. However, the purpose
of our research study was not to assess overall HRQoL, but rather specific domains of HRQoL.
Thus, the model was adapted to fit our research objectives (Figure 2-2). The characteristics of the
environment were excluded, since all patients were recruited from the same health care
institution and were cared for by the same ophthalmologist. Although the original model
developed by Wilson and Cleary (1995) illustrates causal relationships between adjacent
domains, we adapted the model so that relationships could exists between nonadjacent
domains19,127. The premise was that understanding these relationships are important for glaucoma
treatment and management.
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Figure 2-1. Health-related quality of life conceptual model. Developed by Wilson and
Cleary, JAMA 1995; 273(1): 59-65

Figure 2-2. Adapted Wilson and Clearly (1995) model for glaucoma and glaucoma suspect
patients

2.9 Predicting Patient-Reported Outcomes
The term prediction is used in machine learning to estimate the outcome for the value of a new
unobserved variable128. In machine learning, no distinction is made between variables that could
in principle be observed immediately (e.g. predict a patient’s age, given their occupation) and
those that are not observable until some future point in time (e.g. predict whether the patient will
develop glaucoma over the next five years). Thus, the term prediction is relative to the state of
knowledge of the model making the prediction, not relative to the “true” observed value of the
variable. In machine learning, the variables in the model (i.e., input or independent variables) are
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often called predictor variables128. For the context of this thesis, independent variables are
referred to as predictor variables.
Predictive models may help ophthalmologists improve glaucoma management by assessing the
patient’s perceived health status and values. Such an approach is of high interest to governments
which are interested in providing cost-effective, and yet, quality care. Compared to administering
several different PRO instruments, a predictive tool can be an efficient method to assess patient
needs for health care decisions. Studies aiming to predict outcomes or identify factors associated
with an outcome need to go beyond simple regression models and significance of covariates to
make conclusions. A literature review conducted in 2015 identified machine learning approaches
used in clinical vision sciences for image processing and glaucoma diagnosis23. Most of the
machine learning techniques in glaucoma research were used to improve the diagnosis of
glaucoma23.
Identifying predictor variables for HRQoL have been done in studies among conditions such as
obesity, schizophrenia, multiple sclerosis, back pain, other chronic conditions and patients after
undergoing surgical procedures127,129–135. However, the methodology used in identifying
predictor variables is not consistent across studies. Benedict et al. (2005) and Kowalchuk et al.
(2009) performed multivariable linear and/or logistic regression methods to identify the best
subset of predictors of HRQoL and patient outcomes130. Bow-Thomas et al. (1999), Horng et al.
(2005) and Khedmat et al. (2007) used stepwise regression to identify significant variables to be
included in their predictive models129,132,134. Khedmat et al. (2007) further assessed the model
accuracy of the derived model134. Hatzmann et al. (2009) and Heslin et al. (2011) used structural
equation modeling to determine a final model to predict HRQoL133,136. Wang et al. (2013)
identified factors associated with HRQoL among overweight/obese adults by using multivariable
modeling and selected the best model based on Mallow’s complexity parameter (Cp), R-squared,
adjusted R-squared statistics135.
There were a few studies that used machine learning techniques to predict PROs among patients
with ocular conditions95,137. Browne et al. (2012) assessed model performance and model fit to
estimate a model that predicts PROs (four generic HRQoL instruments and the NEI VFQ-25)
based on vision-specific measures95. The model performance was assessed using mean absolute
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error (MAE), mean square error (MSE) and root mean square error (RMSE), and model fit was
assessed using R-squared 95. The ordinary least squares model was chosen as the best-performing
model, based on the lowest RMSE and MAE and highest R-squared 95. The only clinical
variables included in the model were visual acuity, contrast sensitivity and visual field95.
Hirasawa et al. (2014) used the Sumi Visual Disability Questionnaire to predict VRQoL using
only visual field and visual acuity, and the prediction error was calculated using RMSE with
leave-one-out cross validation137. They found a smaller RMSE with the machine learning model
compared to the linear and stepwise regression model137.
Our research study is interested in performing machine learning techniques to identify variables
that are most predictive of PROs. Not only were important clinical variables used, but important
characteristics of patients that were not collected typically during a comprehensive eye exam
were used as well.

2.10 Summary of the Gaps in the Literature
There is a growing recognition that it is important to assess patients’ health outcomes in a
multidimensional approach to include PROs, because there are many factors that influence
health. Despite the benefits, it may be burdensome for ophthalmologists and patients to routinely
assess PROs in clinical practice and there are no clinical guidelines specifying the use of PROs.
Although, research studies have incorporated PROs, there is no specification as to which PRO is
best to be used in ophthalmic practice. At a time when health policy makers are asking for
metrics of quality of care, it is incumbent upon health care providers to develop and implement
systems that efficiently address this need.
The importance of increasing patient input into health care decision making has become a very
contemporary topic in many countries, including Canada. However, it has also been recognized
that, this needs to be done in the most efficient way possible in order to be implemented and
sustainable. Thus, our research study aims to identify predictor variables that are most strongly
associated with PROs through rigorous methodologies that previous studies among glaucoma
patients have not addressed.
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Chapter 3

3

Thesis Rationale and Thesis Objectives

3.1 Thesis Rationale
There is an increased need to incorporate PROs in clinical care. In addition to the clinicians’
assessment of the patient, PROs are necessary for tailored optimal care, because although
patients have good clinical outcomes, their perceptions of their health state may be poor and vice
versa. Obtaining data on PROs is also useful for policy makers to incorporate direct patient
input into health care decision making policies. However, incorporating PROs to daily clinical
practice can be challenge. A stream-lined process that would provide the highest yield of
relevant data would allow for broad uptake in the clinical setting. Thus, my thesis aimed to
answer the following question: What clinical and/or demographic variables are most predictive
of important PROs? Pertaining to my project and patient population, important PROs are defined
as social support and community integration, depressive symptoms, vision-related quality of life
(VRQoL) and preference based health-related quality of life (HRQoL).

3.2 Thesis Objectives
1. To assess social support and community integration as measured by the Community
Integration Questionnaire (CIQ), and determine which clinical and/or demographic
variables are associated with the overall score, in glaucoma suspects and patients
diagnosed with glaucoma.
2. To assess depressive symptoms as measured by the Patient Health Questionanire-9
(PHQ-9), and determine which clinical and/or demographic variables are associated with
the presence or absence of depressive symptoms, in glaucoma suspects and patients
diagnosed with glaucoma.
3. To assess VRQoL as measured by the National Eye Institute Visual Function
Questionnaire-25 (NEI VFQ-25), and determine which clinical and/or demographic
variables are associated with the composite score, in glaucoma suspects and patients
diagnosed with glaucoma.
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4. To assess the preference-based HRQoL as measured by the Time Trade-Off (TTO)
technique and determine which clinical and/or demographic variables are associated with
the utility values, in glaucoma suspects and patients diagnosed with glaucoma.
5. To develop models for predicting social support and community integration, presence of
depressive symptoms, VRQoL and preference-based HRQoL based on clinical and/or
demographic variables, and validate the resulting models
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Chapter 4

4

Methods

This chapter begins with an overview of the study design and sampling procedures (Section 4.1),
sample size calculation (Section 4.2), and data collection methods (Section 4.3). Following is an
overview of the predictor variables measured (Section 4.4) and outcome measures used (Section
4.5). This chapter concludes with a detailed description of the statistical analysis procedures
(Section 4.6).

4.1 Study Design and Sampling Procedures
This study was a cross-sectional design. Two hundred and fifty patients who were identified as
glaucoma suspects (refer to Section 4.4.2.5 for definition of glaucoma suspects) or had been
diagnosed with glaucoma were recruited from a single ophthalmic practice with an
ophthalmologist specializing in glaucoma, at the Ivey Eye Institute, St. Josephs Health Care
London, Ontario. Patients were sequentially recruited from February to August 2016 using
convenience sampling. As patients came in for their regular ophthalmology visits, their eligibility
was determined by the ophthalmologist. Inclusion criteria included patients who were diagnosed
with glaucoma or who were glaucoma suspects and their willingness and ability to answer the
questions in the measurement tool. Exclusion criteria included patients who were unable to
participate due to language restrictions. All participants received a complete explanation of the
purpose and procedures involved in the study and patient concerns were addressed prior to study
participation. Both verbal and written informed consent was obtained from all participating
patients. The study was initiated after approval by Western University’s Research Ethics Board
(refer to Appendix A for the approval letter) and Lawson Health Research Institute’s Clinical
Research Impact Committee.

4.2 Sample Size Calculation
Since the Community Integration Questionnaire (CIQ) and Patient Health Questionnaire-9
(PHQ-9) measures were not previously assessed in our study population, the effect size for the
sample size calculation was determined based on the Time Trade-Off (TTO) technique. The
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effect size for the TTO utility score was determined based on the study conducted by Sharma et
al. (2000)138. The power approach was used which involved specifying a hypothesis test,
significance level (a), effect size and value of the power. For purposes of the sample size
calculation, the null hypothesis is defined as the model with just the intercept (i.e., when all
predictor variables = 0). The null hypothesis is testing whether the null model (i.e., model with
only the intercept) is better than the alternative model with the predictor variables added. We
determined the required Cohen’s f2 effect size for an F-test to be 0.2 and specified that such an
effect be detected with 80% power, when the significance level is a=0.05 with 27 predictor
variables (this includes the levels within a categorical variable). An online sample size calculator
was used to calculate an a-priori sample size for multiple regression139. To compute the sample
size, the online calculator used nine formulas that is provided in Appendix B139.
The minimum required sample size calculated was n=139. Accounting for subject recruitment,
we determined a study sample size of n=250 to be sufficient. In comparison, sample sizes of
previous observational studies ranged from 73 to 32587,95,96,119,124,125,138,140–153.

4.3 Data Collection Methods
Clinical and demographic variables were collected by two methods: face-to-face interviews and
retrospective medical chart review. All data were recorded on paper data collection forms and
then single data entry was performed into a password protected Microsoft Excel spreadsheet.
Data quality checks were performed at random.

4.3.1 Face-to-face Interview
After the clinical examination, questionnaires were delivered in person. The actual
administration of the questionnaires was a combination of interviewer administered and selfadministration modes. Patients were interviewed under standardized conditions to determine five
demographic variables and utility values by the Time Trade-Off (TTO) technique. The
interviews were conducted by a single interviewer. All other questionnaires – Community
Integration Questionnaire (CIQ) and Patient Health Questionnaire (PHQ-9) and the National Eye
Institute Visual Function Questionnaire-25 (NEI VFQ-25) were completed by the patient in
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paper format. The researcher was present while the patient was completing the questionnaires
and was available to address any patient concerns and administer the questionnaire if patients
had difficulties completing the questionnaires on their own.

4.3.2 Retrospective Chart Review
Clinical variables were obtained mainly through medical chart review or in combination with
face-to-face interviews. A total of thirteen predictor variables were measured.

4.4 Predictor Variables
The Wilson-Cleary conceptual model19 was adapted (Figure 2-2), review of the literature and
expert opinions were used to refine and select variables to measure. Predictor variables were
categorized to ensure adequate representation in each category.

4.4.1 Demographic Characteristics
Demographic characteristics collected include: age, sex, income, education, living arrangement
and use of mobility aids. Typically, age and sex are variables that are collected and recorded in
the patient’s medical charts. However, income, education, living arrangement and use of
mobility aids are variables that are not collected during a typical comprehensive eye exam.

4.4.1.1

Age

The Century Month Code (CMC) is a form of reporting dates that is used in major surveys such
as the Demographic and Health Survey (DHS), to simplify working with data coded by month
and year154. It represents dates using a reference date of January 1st 1900. CMC is calculated by
multiplying the difference between the year of interest and 1900, by 12 and then adding the
month:
CMC (month, year) = 12 (year – 1900) + month
A continuous measure of age in years was calculated by computing the difference between the
CMC of the date of visit and the date of birth.
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4.4.1.2

Sex

Sex is a binary variable that was coded as Female = 1 (the reference category) and Male = 2.

4.4.1.3

Income

Current yearly income status of the patient was collected during the face-to-face interview.
Patients were asked to choose their income range from the following eight categories: less than
$10 000, $10 001 to 25 000, $25 001–$50 000, $50 001–$75 000, $75 001–$100 000, $100 001–
$125 000, $125 001–$150 000 and greater than $150 000. To collect accurate income data these
8 categories were used. Prior to analysis, to obtain a better distribution of the data and exclude
categories that do not contain any responses, the eight income categories were grouped into three
categories: less than $25 000 (code = 1; the reference category), $25 000–$50 000 (code = 2) and
greater than $50 000 (code = 3).

4.4.1.4

Education

Patients were asked to select their highest level of education completed from the following seven
categories: some high school or less, completed high school, additional training (apprenticeship,
trade or vocational school, etc.), college degree, undergraduate university, postgraduate
university and advanced professional degree. For better data distribution, the response categories
were collapsed to provide a binary variable: completed high school or less (code = 0; the
reference category) and completed more than high school (code = 1).

4.4.1.5

Living Arrangement

Patients were asked to select their living arrangements given the following seven categories:
home alone, home with spouse, home with family, home with caregiver, nursing home, longterm care home and retirement home. To exclude categories with no responses and for a better
distribution of the data, the seven response categories were collapsed into three categories: home
alone (code = 1; the reference category), home with family/spouse/caregiver (code = 2) and
nursing/retirement home (code = 3).
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4.4.1.6

Use of Mobility Aids

Patients were asked if they used mobility aids, and if they responded yes, then they were asked to
specify the type of mobility aids used: a cane, walker, wheelchair or motorized scooter. This
variable was dichotomized as: does not use mobility aid (code = 1; the reference category) and
does uses mobility aid (code = 2).

4.4.2 Clinical Characteristics
The clinical characteristics collected include: best corrected visual acuity, number of
comorbidities, number of ocular conditions, number of ocular procedures, glaucoma stage, time
since diagnosis, initial treatment. These clinical characteristics are typically collected during a
comprehensive eye exam.

4.4.2.1

Best Corrected Visual Acuity

Vision function is measured quantitatively through visual acuity and visual field assessments.
Visual acuity measures the ability of the eye to identify shapes and details of objects at a given
distance and to detect any changes in vision70. Best corrected visual acuity (BCVA) refers to the
measurement ‘with correction’, such as with glasses or contact lens. Snellen acuity chart was
used to test visual acuity for the study patients, in addition to Count Fingers (CF), Hand Motion
(HM), Light Perception (LP) or No Light perception (NLP) for those patients whose vision was
worse than 20/400.
The International Classification of Diseases (ICD-9) categorizes vision as: mild vision
impairment (code = 1; the reference category), moderate vision impairment (code = 2) and legal
blindness (code = 3). Mild vision impairment is defined as BCVA between 20/32 and 20/63;
moderate vision impairment is defined as BCVA between 20/80 and 20/160; legal blindness is
defined as BCVA is 20/200 or worse71. With regards to eye diseases that affect peripheral vision,
as in glaucoma, it appears that the worse-seeing eye has a stronger influence on VRQoL118. Thus,
the BCVA in the worse-seeing eye was obtained from the medical charts.
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4.4.2.2

Number of comorbidities

First, patients were asked if they had any other comorbidities, and if yes, they were asked to
specify the type of comorbidity by selecting from the following categories: cardiovascular,
neurological, respiratory, immunocompromised, cancer, infectious disease, musculoskeletal,
gastrointestinal, endocrine/metabolic, psychological and other.
Secondly, the researchers verified and validated the listed comorbidities by reviewing patients’
medical charts. For analysis, the number of comorbidities was identified and treated as a
continuous variable.

4.4.2.3

Number of Ocular Conditions

Patients were asked if they had any other ocular diseases besides glaucoma. All conditions such
as cataracts, pseudoexfoliation syndrome, age-related macular degeneration were recorded.
Patients’ responses were verified through medical chart reviews. This variable was treated as a
continuous variable.

4.4.2.4

Number of Ocular Procedures

Patients were asked if they had any ocular procedures performed, such as cataract surgery.
Patients’ response were verified through medical chart reviews. Number of ocular procedures
was treated as a continuous variable.

4.4.2.5

Glaucoma Stage

The Canadian Ophthalmological Society defines four stages of glaucoma based on clinical
characteristics22:
Suspect Glaucoma (code = 1; the reference category): suspicious cup-to-disc (C/D)
asymmetry of >0.2.
Early Glaucoma (code = 2): Vertical C/D ratio of <0.65, and/or mild visual field defect not
within 10 degrees of fixation, mean deviation(MD) better than -6dB.
Moderate Glaucoma (code = 3): Vertical C/D ratio between 0.7 and 0.85, and/or moderate
visual field defect not within 10 degrees of fixation, MD from -6dB to -12dB.
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Severe Glaucoma (code = 4): Vertical C/D ratio of >0.9, and/or visual field defect within 10
degrees of fixation, MD worse than -12dB.
Glaucoma stage was determined from the most recent clinical characteristics found in the
patient’s medical chart, and was treated as a categorical variable with four levels.

4.4.2.6

Time Since Diagnosis

Time since glaucoma or glaucoma suspect diagnosis was obtained from the patient’s medical
chart. The difference between the date of study visit and date of diagnosis was computed as a
continuous measure. To improve the precision of this measure, the unit of measure was
converted from years to months.

4.4.2.7

Initial Treatment

The treatment options for the study patients were obtained from medical charts, which included:
medication (code = 0, the reference category), selective laser trabeculoplasty (SLT) (code = 1) or
observation (code = 2). This variable was treated as a categorical variable with three levels.

4.5 Patient-Reported Outcome Measures
Four separate measurement tools were used to determine each of the four outcomes: patient’s
level of social support and community integration, presence of depressive symptoms, visionrelated quality of life (VRQoL) and preference based HRQoL.

4.5.1 Community Integration Questionnaire
The CIQ was used to provide a quantitative indicator for the level of social support and ability to
perform appropriate roles at home and within the community108. The CIQ contains 15-items and
uses behavioural items of integration to achieve better reliability60. The CIQ used for this study is
presented in Appendix B.
The CIQ was administered during the face-to-face interview process and took the patients about
5 to 10 minutes to complete. The CIQ was completed by the patient, with an interviewer present
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for assistance. The original scoring procedures were followed for this study, which produced a
total score and three subscale scores107,108:
Home Integration: 0 to 10 points; consists of 5 items assessing activities that were
typically done independently such as housework, child care, household shopping, meal
preparation and planning social arrangements. The response options included: yourself
alone, yourself and someone else or someone else.
Social Integration: 0 to 12 points; consists of 6 items assessing frequency of activities
that relate to leisure activities, shopping, personal finance management, visiting family
and friends, having a best friend and engaging in leisure activities. The response options
included the frequency of participating in such activities and with whom these activities
are done with.
Productive Activities: 0 to 7 points; consists of 4 items assessing frequency of activities
that relate to volunteer activities, travel, student and employment status.
The total CIQ score ranges from 0 to 29, with a higher score representing a higher level of social
support and complete community integration108. The CIQ was adapted for use in our research
study. One of the options for item 10, ‘Mostly with friends who have head injuries’ was changed
to ‘Mostly with friends’ to be applicable to our patient population. All other items remained the
same. The total CIQ score was analyzed as a continuous outcome using linear regression.
Prior studies mainly assessed psychometric characteristics of the CIQ in a sample of traumatic
brain injury patients, thus little is known about the psychometric properties among other patient
groups101. However, a cross-sectional study published in 2010, tested the CIQ across various
debilitating diseases, aging and traumatic conditions74. In addition, a recent study assessed the
CIQ in a geriatric population109. Seale et al. (2002) reported relative reliability coefficients for
home integration (r=0.71), social integration (r=0.70), productive activities (r=0.63) and CIQ
total (r=0.81). In 2000, Cusick et al. reported intraclass correlation coefficients (ICC) as a
measure of the test-retest reliability of the CIQ: 0.88 for home integration, 0.66 for social
integration, 0.80 for productive activities and 0.86 for CIQ total155. Most recently, Singh &
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Sharma (2015), reported excellent ICC among a geriatric population (ICC=0.99)109. Overall,
studies have reported adequate to excellent test-retest reliability across the three domains.
Studies assessing the psychometric properties of the CIQ have reported evidence for discriminant
validity comparing disabled to nondisabled individuals, differentiating scores among individuals
living independently and with support and moderate to strong interrater reliability101,106,108. Past
studies have reported the total CIQ score to be adequate in assessing community integration105.
Reliability of the CIQ is generally acceptable and the validity was evaluated by difference in
CIQ scores by sex, age and wheelchair use106.

4.5.2 Patient Health Questionnaire - 9
The PHQ-9 was used to measure the presence of depressive symptoms. The PHQ-9 contains 9items that represent DSM-IV specific diagnosis of depressive disorder115. The PHQ-9 used in our
study is presented in Appendix C.
The PHQ-9 was completed by the patient, with an interviewer present for assistance. It took the
patient about 5 minutes to complete the questionnaire. The PHQ-9 provides a total score that
translates into the following four categories: minimal, mild, moderately severe and major
depressive symptoms. Patients rate the difficulty of performing tasks such as: work, home
activities and associations with others. Patients were asked how much each symptom has
bothered them over the past two weeks, with respect to the following response options and
scores: “not at all” (score = 0), “several days” (score = 1), “more than half the days” (score = 2)
and “nearly every day” (score = 3). A final item assessed the degree to which the depressive
symptoms influenced social, functional and occupational impairment156. The total PHQ-9 score
was scored on a scale from 0 to 27, with the higher score representing more severe depressive
symptoms. The scores assigned to the PHQ-9 categories are as follows: minimal symptoms (5 to
9), mild symptoms (10 to 14), moderately severe symptoms (15 to 19) and major depressive
symptoms (> 20). The scoring scale used for PHQ-9 does not account for scores less than five.
For our research study, to capture the PHQ-9 total scores of less than five, the score was
dichotomized to the presence or absence of depressive symptoms. Thus, the score was
categorized as ‘no depressive symptoms’ (code = 0; the reference category) and ‘some
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depressive symptoms’ (code = 1). ‘No depressive symptoms’ consisted of a PHQ-9 score
ranging between zero and four and ‘some depressive symptoms’ consisted of a PHQ-9 score
greater than four. The PHQ-9 score was analyzed as a binary outcome using logistic regression.
The PHQ-9 has strong internal and test-retest reliability as well as construct and factor-structure
validity156. PHQ-9 demonstrated good internal reliability, with Cronbach’s coefficient alpha
values of 0.842, 0.846, 0.816 across three different trials112. Limited studies investigated the
validity of PHQ-9. The sensitivity of the PHQ-9 detecting depressive disorders was fair
(sensitivity=0.64)114. Kroenke et al. (2001) assessed the construct validity of the PHQ-9 using
the Short Form General Health Survey and reported 88% sensitivity and specificity for a PHQ-9
score ³10115.

4.5.3 National Eye Institute Visual Function Questionnaire - 25
The NEI VFQ-25 was used to determine the vision-related quality of life (VRQoL) of the
patients. It contains 25 items, 24 of which are vision-related. The NEI VFQ-25 used in our study
is presented in Appendix D. The items were divided into three parts: general health and vision,
difficulty with activities and responses to vision problems. The items were scored according to
12 domains: general health (1 item), general vision (1 item), ocular pain (2 items), near vision (3
items), distance vision (3 items), social functioning (2 items), mental health (4 items), role
functioning (2 items), dependency (3 items), driving (3 items), colour vision (1 item) and
peripheral vision (1 item)157. The driving score was only documented for patients who were
drivers. Mean composite and subscale scores can be obtained from this questionnaire. Most
items were recorded on a scale of 1 to 5 or 1 to 6, each item was then converted to a 0 (worst
possible score) to 100 (best possible score) scale18. For purposes of this study, only the NEI
VFQ-25 composite score was used to capture an overall measure of VRQoL. The NEI VFQ-25
composite score was an average of the 11 vision-related domains, with the exclusion of general
health. The general health item was treated as a stand-alone item157. The composite score ranged
from 0 to 100, with a higher score representing better visual functioning. By taking the average
of each domain, as opposed to average of each item, equal weight was given to each domain157.
NEI VFQ-25 was completed by the patient, with an interviewer present for assistance. Patients
were asked to respond to all items as though they wore glasses or contact lenses to correct their
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vision. It took the patient about 10 minutes to complete the questionnaire. The NEI VFQ-25
score was analyzed as a continuous outcome using linear regression.
Internal consistency estimates of each domain ranged from 0.71 to 0.85, representing an
acceptable reliability157. Berdeaux et al. (2005) and Revicki et al. (2010), reported Cronbach’s
alpha coefficients for the NEI VFQ-25 composite score of 0.94 and 0.96, respectively118.
Mangione et al. (1998) defined the psychometric properties of the NEI VFQ-25 and suggested
that the 12 domains represent a broad dimension of VRQoL100. Mangione et al. (2001) tested the
psychometric properties of the NEI VFQ-25 and reported evidence of between group validity157.
The reliability and validity of NEI VFQ-25 was reported to be similar as the NEI VFQ-51119. On
average the NEI VFQ-25 score predicts about 92% of the variance in the NEI VFQ-51 score157.
Thus, previous studies demonstrated good reliability and validity of the NEI VFQ-25 in terms of
measuring vision-related outcomes across various ocular diseases158.

4.5.4 Time Trade-Off Technique
The TTO technique was used to obtain utility values. Patients were asked a 2-part question:
1. “How many years do you expect to live?”
2. “Suppose that there was a new technology that could restore your eyesight to perfectly
normal in both eyes. The technology always works but decreases the length of time you
live. What is the maximum number of years, if any, that you would be willing to give up if
you could receive this technology and have perfect vision for your remaining years?”
The TTO utility values were calculated by dividing the number of years the patient is willing to
give up for perfect vision by the number of years expected to live, and subtracting the obtained
proportion from 1.0148. The utility value ranges between 0 (death) to 1 (perfect visual health). For
example, consider a patient who expects to live for another 20 years and is willing to give up 5
years for perfect vision. The patient’s utility value would be generated by subtracting the
proportion of remaining years traded for perfect vision (0.25 or 25%) from the state of perfect
visual health (1.0 or 100%). The resulting utility value of 0.75 (75%), represents the patient’s
perception of their HRQoL. The larger the proportion of remaining years that a patient is willing
to trade for perfect vision, the lower the associated utility value. Generally, the TTO utility
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values are analyzed using linear regression. However, given the data obtained for our study
population, linear regression would not be the best fit, since it would result in a zero-inflated
model. Therefore, for this study the utility values were categorized as those ‘not willing to give
up any years of life’ (code = 0; the reference category) and those ‘willing to give up some years
of life’ (code = 1). The format of the TTO technique used in our study is presented in Appendix
E. The TTO technique was completed by the patient, with an interviewer present for assistance.
The TTO utility score was analyzed as a binary outcome using logistic regression.
Previous studies have demonstrated the validity of the TTO technique with respect to best
corrected visual acuity (BCVA) in the better-seeing eye146. TTO technique has shown good
reproducibility159. Hollands et al. (2001) showed good reliability (ICC=0.76) of the TTO
technique among patients with ocular disease160.

4.6 Statistical Analysis
4.6.1 Univariate Analysis
Predictor variables were explored one by one, using univariate analysis. Descriptive statistics
were computed for all predictor variables and outcome variables. In order to understand the
distribution of each predictor variable, frequencies were calculated for categorical variables (sex,
income, education, living arrangement, use of mobility aid, BCVA, glaucoma stage, initial
treatment, PHQ-9 and TTO). In order to understand the central tendency and distribution of
continuous predictor variables, means and standard deviations were calculated for continuous
variables (age, number of comorbidities, ocular condition, ocular procedures, time since
diagnosis, CIQ and NEI VFQ-25).

4.6.2 Missing Data
Missing data are classified in terms of their probability as they relate to the predictor variable
(observed data) and outcome variables (unobserved data). Missing at random (MAR) is when the
probability of missing data may depend on the predictor variables, but not on the outcome161.
Missing completely at random (MCAR) is when the probability of missing data are not related to
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the predictor variable and outcome variables161. Missing not at random (MNAR) is when the
probability of missing data is related to the outcome variable161. MCAR and MAR can be
imputed without introducing systematic bias162.
Missing data can occur for many reasons. In our research study, it was due to patients’ refusal to
provide their income range and respond to the TTO technique. We believe the missing data were
MAR conditioned on the other variables (i.e., education). The nonresponse rate was 7.2% (n=18)
and 1.2% (n=3) for income and the TTO value, respectively. Considering that TTO value was an
outcome of interest and the nonresponse rate was small, these individuals (n=3) were excluded
from all analyses, reducing the sample size of 250 to 247.
Imputation is the method used to fill in missing data. The advantage of using imputation is to
provide a complete data set for analyses, increase efficiency and reduce bias. Single imputation
is a process that analyzes the observed responses for the missing variable and provides one
plausible response for the missing data point. The advantage of single imputation is that once the
values are filled in, performing the necessary complete-data analyses are straightforward163. The
disadvantage of single imputation is that it underestimates the uncertainty and variance. To
overcome this disadvantage, multiple imputation provides a set of plausible responses and
considers the uncertainty both within and between imputations161. In multiple imputation, the
missing values are replaced by two or more stimulated values to create imputed datasets163.
Statistical analyses are then conducted using each of the imputed datasets to calculate a point
estimate that is adjusted for the missing data uncertainty163. The objective of multiple imputation
is to provide valid statistical inferences163.
To handle the missing data for income in our dataset, an ordinal variable, multiple imputation
was performed, using the ordered logistic regression imputation method in STATA 13. Literature
suggest that values imputed between 2 and 10 are sufficient to obtain valid inferences and since
the percentage of missing values is low for income, thus we imputed 10 times163. We then
analyzed the multiple imputed data with multivariable linear and logistic regression. This method
of multiple imputation was used to estimate regression coefficients, but not for stepwise
regression and Classification and Regression Tree (CART) analyses.
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It is more difficult to handle missing data in prediction modelling, because for nonlinear models
like CART there are no standard rules for combining models from different imputations. This is
in contrast to Rubin’s Rules, which was used for the inference analyses163. Rubin’s Rules are
based on the approach of combining the models obtained from multiple imputation to produce
overall estimates, confidence intervals and p-values. Since our predictive modelling is not
intended for inference, it is less crucial to consider the uncertainty (e.g., standard errors of
estimates), whereas for inference modelling uncertainty was important to consider. Furthermore,
in our research study less than 10% of all measured variables were missing (entirely from the
income variable). Thus, for prediction analyses, we performed single regression imputation using
the mode, in which the mode of the 10 imputations was treated as the actual income value and
manually replaced to create a complete data set. This approach increases variance, in comparison
to the traditional mean substitution method. This completed data set was used to perform
stepwise regression and CART analysis.

4.6.3 Bivariate Analysis
Bivariate analysis was performed to assess the unadjusted effect estimates and check whether
each predictor variable and outcome were associated. Each of the 13 predictor variables were
individually investigated for association with all four outcomes, using simple linear and logistic
regression analyses.

4.6.4 Associations Between Predictor Variables
Investigating the association between the predictor variables can provide information regarding
difficulties when assessing the effects (i.e., if two predictor variables present high correlation,
then the effect of one, when adjusted for the other predictor variables, cannot be estimated with
high precision)164. Comparisons can be made between categorical and categorical, or continuous
and continuous, or categorical and continuous variables.
Pearson correlations were used to assess the association between pairs of continuous predictor
variables. Correlation varies between -1 (perfect negative linear correlation) and +1 (perfect
positive linear correlation), and 0 represents no correlation. The Pearson correlation coefficient
threshold absolute value of 0.6 was used as a cut-off indicating a strong association between the
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variables165. If a threshold above 0.6 was identified, then a significance test was conducted to
confirm the association.
Chi-square tests were used to assess the association between pairs of categorical predictor
variables. Chi-square test is based on the difference between the expected and observed
frequencies. Probability ranges from 0 (categorical predictor variables are independent) to 1
(categorical predictor variables are dependent). The significance of the relationship between the
predictor variables was defined at a<0.05.
T-tests and one-way ANOVA were used to assess the associations between pairs of continuous
and categorical predictor variables. T-test assess whether the means of two groups are
statistically different from each other. ANOVA assess whether the means of three or more
groups are statistically different from each other. Statistical significance was determined at
a<0.05. T-test was used for the categorical variables with two levels: sex, education and use of
mobility aid. One-way ANOVA was used for the categorical variables with more than 2 levels:
income, living arrangement, BCVA, glaucoma stage and initial treatment.

4.6.5 Regression Diagnostics
The following assumptions were considered to examine the distribution of the predictor
variables: linearity, normality, homoscedasticity, multicollinearity, model specification,
independence. The linearity assumption considers that the relationship between the predictor
variables and the outcomes should be linear. Component-plus-residual plot was used to assess for
non-linearity. The normality assumption requires that the residuals are normally distributed,
which was assessed using quantile-quantile (Q-Q) plot. The homoscedasticity assumption
requires that the error variance be constant, which was assessed using residual-versus-fitted plot.
Lastly, the variance inflation factor (VIF) was used to test for multicollinearity. A VIF of 10 was
used as the rule of thumb to indicate an acceptable level of multicollinearity166.

4.6.6 Multivariable Regression Analysis
Inferential statistical analysis was performed to generalize about the population from which the
sample was taken167. Valid inference means that the standard errors of the parameter estimate are
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valid, confidence intervals have the desired coverage probability and p-values correctly describe
the probability of observing the absolute value of the observed parameter estimate168.
Multivariable linear and logistic regression analyses were performed using STATA 13.

4.6.6.1

Multivariable Linear Regression

A multivariable linear regression model was built to identify the predictor variables associated
with the following two outcomes: social support and community integration; and VRQoL.
Multivariable linear regression models the relationship between a set of predictor variables on
the likelihood of one continuous outcome, by fitting a linear equation to the observed data.
The equation for systematic part of the model is:
!(#|%) = () + (+ %+ + (, %, + ⋯ + (. %.
where !(#|%) is the expected value of the outcome at a given value of a set of predictor variables
%/ (i = 1, 2, … n) are the predictor variables
() is the intercept
(/ (i = 1, 2, … n) are the slopes for each variable (i.e., regression coefficients)
The intercept, (() ), denotes the probability of the outcome when %/ = 0, which can be
interpretable by “centering” the continuous predictor variables. For the continuous predictor
variables, the coefficient, (/ ,is interpreted as the change in the expected outcome for a one unit
increase in one predictor variable, while holding all other predictor variables in the model
constant. For categorical predictor variables, we get the probability of the outcome in the group
with respect to the reference group, adjusting for all other predictor variables.
There is also a random part of the model, in which each observation of the outcome is modeled
in terms of an error term168.
The equation for the random part of the model is:
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#/ = ! #/ %/ + e/ = () + (+ %+/ + (, %,/ + ⋯ + (. %./ + e/
where e/ is the error term about an average determined by %/
%1/ (i = 1, 2, … n) is the value of the predictor variable %1 for observation i
We assume that e/ is normally distributed with a mean of zero.
Linear regression diagnostics were checked to ensure the data met the assumptions of linear
regression and to avoid potential bias of the parameter estimates. Normality of residuals was
assessed using residual plots. Homogeneity of variance of the residuals (homoscedasticity) was
assessed using a residual-versus-fitted plot. Multicollinearity was assessed using variance
inflation factor (VIF). Linearity was assessed for each continuous predictor variable using
component-plus-residual plots. Specification error was tested using a link test.

4.6.6.2

Multivariable Logistic Regression

A logistic regression model was built to identify the predictor variables associated with the
following two outcomes: presence of depressive symptoms and preference based HRQoL.
Logistic regression models the effect of a set of predictor variables on the likelihood of one
binary outcome.
The equation for multivariable logistic regression is:
23456 7/ = () + (+ 8+ + (, 8, + ⋯ + (. 8.
where 7/ is the probability of the outcome
8/ (i = 1, 2, … n) are the predictor variables
() is the intercept
(/ (i = 1, 2, … n) are the regression parameters
23456 is the ln (odds of the outcome), where odds is (

9:
+;9:

)
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The intercept (() ) denotes the log of the odds of the outcome when all 8/ = 0, which may or may
not contain meaningful interpretation, but is still an integral part of the model. We obtain the
odds of the outcome when 8/ = 0 by exponentiating the intercept. By exponentiating the
regression coefficient ((/ ), we get the odds ratio of the outcome. For the continuous predictor
variables, exponentiating the coefficient will provide the odds ratio of the outcome for every one
unit increase in 8/ , adjusting for all other predictor variables. For categorical predictor variables,
we get the odds ratio of the outcome comparing the higher category of 8/ to its reference
category, adjusting for all other predictor variables.
Logistic regression diagnostics were checked to ensure linear relationship with the logit of the
outcome and absence of multicollinearity. Linearity between the continuous predictor variables
and the logit of the outcome was assessed using scatter plots. Multicollinearity was previously
assessed using VIF.

4.6.7 Variable Selection for Building Prediction Models
The primary aim of prediction is to minimize error rather than identifying associations168.
Variable selection for prediction purposes is intended to select the best set of predictor variables.
In terms of prediction, variable selection is valuable so that we can save time and money by not
measuring redundant predictor variables. The aim is to construct a model that predicts the value
of the outcome given the predictor variable. Stepwise regression and Classification and
Regression Tree (CART) are machine learning approaches to variable selection.
Some predictor variables are well-established in literature as being highly associated with the
outcome, thus predictor variables may be included in the model for face validity without
considering the strength or statistical significance168. Selecting predictor variables based on pvalues have been criticized, since no significance of an effect is not equal to the absence of an
effect168. Variable selection is important as it aims to determine which variables are strong
predictor variables of the outcome and to find the right balance between goodness of fit and
parsimonious model. Variable selection can improve interpretability and accuracy of the
predictions. A parsimonious model is one that achieves a desired level of prediction with as few
predictor variables as possible.
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With building the “best” predictive model, the issue lies in having to choose predictor variables
from a larger set169. It is not just sufficient to perform automatic statistical variable selection, but
it is important to consider clinical significance as well.

4.6.7.1

Stepwise Regression

There are several different methods used to select predictor variables when fitting a regression
model. Forward selection starts with no predictor variables in the model and then tests the
addition of each predictor variable. Backward elimination starts with all predictor variables in the
model and then tests the removal of each predicator variable. Stepwise regression is combination
of forward selection and backward elimination. It is an automated approach used in exploratory
model building to select predictor variables. During this method, predictor variables are
systematically added and/or removed, beginning with a model that has all the variables in it. The
predictor variables that are dropped during stepwise regression may still be correlated with the
outcome, but provide no additional explanatory effect beyond the predictor variables already
included in the model168. The number of possible models is dependent on the number of
predictor variables170. For example, five predictor variables yield 25 = 35 possible regression
models. These models are fit based on a criterion, from which the best model is chosen.
Automatic methods are useful when there are many predictor variables and it is not feasible to fit
all possible models.
Information criteria is a measure of goodness of fit that takes into account both predictive
accuracy and model complexity. Under-fitting a model may not capture the true variability of the
outcome, and over-fitting a model can lose generalizability. Akaike Information Criterion (AIC)
was introduced as a tool for optimal model selection:
<=> = −2ℓ + 2B
where ℓ is the maximized log-likelihood
B is the number of parameters included in the model
AIC considers both the model fit and number of predictor variables used, it is not a p-value
driven approach. The AIC value is measured as the likelihood of the parameters estimates being
correct for the population based on the observed data. Stepwise regression with AIC
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simultaneously evaluates a subset of possible multiple regression models to find the best
model171. AIC measures the balance between the amount of explanatory power and the model
size. The model with the smallest AIC value is determined as the better model.
We performed stepwise model selection by AIC using R (package ‘MASS’)172.

4.6.7.2

Classification and Regression Trees

CART analysis is a machine learning method used to create a decision tree that predicts the
outcome based on several predictor variables and helps to determine the “most” important
predictor variables of the outcome. It is a visual representation of the relationship among the
important predictor variables and the outcome. Classification tress are for binary outcomes and
regression trees are for continuous outcomes173. The goal is to use a training sample of
observations and find a model to predict values of the outcome from new values of the predictor
variables173. CART also captures interaction effects between predictor variables.
The basic structure and splitting algorithm of CART is shown in Figure 4-1:

Figure 4-1. The basic structure and splitting algorithm of Classification and Regression
Trees

51

Each node is conditioned on a predictor variable, %/ , starting at the root node. The final split is
called the leaf node and the terminal node, ax , indicates that further splitting of the data does not
have enough variance to explain the outcome. CART is built using a splitting algorithm that
splits the data into smaller parts based on yes/no questions with maximum homogeneity174.
Maximum homogeneity is defined by an impurity function (5(6)).
Gini Index is the impurity function commonly used for classification trees. The Gini Index
defines the node splits, where each split maximizes the decrease in impurity173:
E

B, (D|6)

5 6 =1−
FG+

where D is the index of the class
B(D|6) is the conditional probability of class D in node 6
Regression trees do not have classes, instead response vectors of the outcome are used. Like the
Gini index, for regression trees the splitting is made according to the squared residuals
minimization algorithm173:
H5IJ: KJ L [NO PQR SO + NT PQR ST ]
:

where PQR SO , PQR ST is the response vector for the left and right internal nodes
%/ ≤ %/X (5 = 1, 2 … n) is the optimal splitting rule
A larger initial tree was created with recursive partitioning, where a split was determined by
examining all possible split values for each variable to find the best split. Then the tree was
pruned with a cross-validation method, to create an optimal tree and minimize misclassification
error. To validate the tree a cost-complexity parameter (CP) is used. The least CP value indicates
that the cross-validated error of the tree is minimum to determine true predictive power of the
tree. The CP function is175:
Ya Z = Y Z + a|Z|
where T is the number of terminal nodes or complexity of the tree
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Y Z is the resubstitution misclassification error of the tree T
|Z| is the number of terminal (or “leaf”) nodes in the tree

a|Z| is the complexity measure that depends on Z for a given value a
CART analysis was performed using the ‘rpart’ package implemented in R (package ‘rpart’). By
default, ‘rpart’ conducts as many splits as possible, then uses 10-fold cross-validation to prune
the tree.

4.6.8 Model Assessment
Model assessment is based on the models ability to accurately predict new data (i.e., prediction)
and whether the model accurately describes the associations in the current data (i.e., goodness of
fit)168.
To avoid results by chance, the data can be split several different times to create two data sets –
training and validation176. The validation set is used to estimate the error rate of the training set.
Assessing the average performance of a model over the different splits is referred to as crossvalidation. Cross-validation is a model validation technique for assessing how the results will be
generalizable. It is mainly used to estimate how accurately a model will perform and compare the
performance of different models.
Since the data set had 250 observations, we chose to perform leave-one-out cross validation
(LOOCV), where a single observation is used for the validation set and n-1 is used for the
training set177. This procedure is repeated so that each observation in the original data set has
been a part of the validation set. LOOCV evaluates a model based on prediction and is used for
estimating the test error176. In comparison to k-fold cross validation, the LOOCV approach has
less bias and does not overestimate the test error rate, since the training sets used contain n-1
observations177. The LOOCV estimate for the mean squared error (MSE) is the average of I test
error estimates177:
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where ]^!/ is represented by (#/ − #/ ), and #/ is the prediction made for the excluded
observation.
The absolute error (AE) is the difference between the measured and actual values. The mean
absolute error (MAE), standard error (SE) and standard deviations (SD) were used to summarize
the errors and describe the predictive performance of each model. MAE is a good indicator of
average model performance and is widely used in model evaluation178. The MAE is calculated
as:
1
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where _/ (5 = 1, 2, … , I) is the n samples of model errors produced by LOOCV
n is the sample size
SE quantifies the variability of estimated parameters for precision, whereas SD measures the
variability of the data from the mean179. SD of the AE is defined as:
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The underlying assumption with SE is that the errors are unbiased and follow a normal
distribution, which provides a representation of the error distribution. SE of the estimate of MAE
is calculated as:
^!dbc =

^abc
I

4.6.9 Software
All preliminary and main analysis were executed using STATA 13 and R (version 1.0.136)
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Chapter 5

5

Results

This chapter first presents the characteristics of the study population and the results of imputation
(Section 5.1 and 5.2). Following is a discussion of the associations among the predictor variables
(Section 5.3) and a statement of the regression diagnostics performed (Section 5.4).
Section 5.5 provides an overview of all the analyses conducted –bivariate analysis, multivariable
regression analysis, stepwise regression, Classification and Regression Trees (CART), and
model assessment. Section 5.6 presents the results for each of the four PROs – social support and
community integration, presence of depressive symptoms, vision-related quality of life (VRQoL)
and preference-based HRQoL.

5.1 Characteristics of the Study Population
Univariate analysis was performed to determine the characteristics of the study population. A
total of 250 patients consented to participate in the study. The patients’ demographic
characteristics are presented in Table 5-1. The average age of the study population [mean (SD)]
was about 72.9 (10.2) years. The sex distribution was 60% female. The majority of patients were
Caucasian (80%) and lived at home with their family, spouse or caregiver (69%). About half had
completed high school or less (49%) and about 40% had an income of less than $25,000. Only
about 11% used a mobility aid such as a cane, walker, wheelchair or motorized scooter.
The patient’s clinical characteristics are presented in Table 5-2. The majority of patients had
mild vision loss (72%) based on the best corrected visual acuity (BCVA) in the worse-seeing eye
and received medication as their initial treatment (72%). About 33% of the patients were
diagnosed as glaucoma suspects and only about 15% were diagnosed with severe glaucoma. The
average number of comorbidities in the study population [mean (SD)] was 1.6 (1.5), average
number of ocular conditions was 2.1 (1.1), average number of ocular procedures was 1.1 (1.0)
and average time since diagnosis was 100.7 (74.5) months.
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5.2 Missing Data
Imputation of the missing values for the income variable was performed and the distribution of
the pre-imputed values did not greatly differ from the distribution of the post-imputed values
(Table 5-3).

5.3 Associations Among Predictor Variables
5.3.1 Association Between Pairs of Continuous Predictor Variables
The results of the associations between continuous predictor variables are presented in Table 5-4.
Pearson correlations did not reveal any strong linear associations among the continuous predictor
variables: age, number of comorbidities, number of ocular condition, number of ocular
procedures and time since diagnosis.

5.3.2 Associations Between Pairs of Categorical Predictor Variables
The chi-square test results of the associations between categorical predictor variables are
presented in Table 5-5. Significant associations were observed between sex and income. A
greater number of females (46%) had an income of less than $25 000. Sex was also significantly
associated with living arrangement. A greater number of males (77%) were living at home with
others. A significant association was observed between education and use of mobility aid. About
half of the patients who did not use mobility aids, had completed more than high school (54%).
BCVA was found to be significantly associated with the use of mobility aid and glaucoma stage.
Among the patients who did not use mobility aids, significantly more patients had mild visual
acuity loss (92%), compared to only 9% who had severe glaucoma.

5.3.3 Associations Between Pairs of Continuous and Categorical Predictor
Variables
The t-test and one-way ANOVA results for the associations between continuous and categorical
predictor variables are presented in Table 5-6. Age was significantly associated with income,
living arrangement, use of mobility aid, BCVA and glaucoma stage. On average, patients with an
income of less than $25 000, living in a nursing or retirement home, using a mobility aid,
moderate visual acuity loss and severe glaucoma were slightly older. Number of comorbidities
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was significantly associated with sex. Number of ocular conditions was significantly associated
with BCVA. Number of ocular procedures was significantly associated glaucoma stage and
initial treatment. Time since diagnosis was significantly associated with initial treatment. On
average, patients who had medication as their initial treatment, had a higher number of ocular
procedures and greater time since diagnosis.

5.4 Regression Diagnostics
The component-plus-residual plots, Q-Q plots, residual-versus-fitted plots and the variance
inflation factors confirmed the assumption of linearity, normality, homoscedasticity and
multicollinearity, respectively.

5.5 Overview of the Statistical Analyses
5.5.1 Bivariate Analysis for Unadjusted Effects
The bivariate analysis results for social support and community integration; presence of
depressive symptoms, VRQoL and preference-based HRQoL with the demographic and clinical
predictor variables are presented in Tables 5-7 and 5-8; 5-13 and 5-14; 5-19 and 5-20; 5-25 and
5-26, respectively. There was a total of 13 predictor variables included, of which six were
demographic and seven were clinical variables. A significance level of p £ 0.05 was used to
determine variables that were significantly associated with the PRO.

5.5.2 Multivariable Regression Analysis for Adjusted Effects
Multivariable regression analysis results for social support and community integration; presence
of depressive symptoms, VRQoL and preference-based HRQoL are presented in Tables 5-9, 515, 5-21 and 5-27, respectively. All predictor variables identified through review of the
literature, expert opinion and conceptual model were included in the multivariable analyses. A
significance level of p £ 0.05 was used to determine variables that were significantly associated
with the outcome.
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5.5.3 Variable Selection for Developing Prediction Models
5.5.3.1

Stepwise Regression

Stepwise regression by Akaike Information Criterion (AIC) for social support and community
integration; presence of depressive symptoms, VRQoL and preference-based HRQoL are
presented in Tables 5-10, 5-16, 5-22 and 5-28, respectively. The selected model was based on the
lowest AIC value.

5.5.3.2

Classification and Regression Trees

Classification and Regression Tree (CART) is an effective machine learning technique,
commonly used for developing prediction models180. Classification trees are used for categorical
outcomes and regression trees are used for continuous outcomes. Recall that CART qualitatively
expresses the relationship between the predictor variables and each outcome by repeatedly
splitting the data based on one predictor variable. At each split the data is divided into two
groups174. The objective is to create a reasonably small tree to avoid overfitting the data and
identify the relevant predictor variables. To avoid overfitting, after the splitting procedure creates
the initial tree with the maximum number of splits, the tree is pruned to obtain the optimal tree
with the most important variables. When a pruned tree results in zero splits, this suggests that
there isn’t enough signal within the data to justify a tree model.

5.5.4 Model Assessment for Developing Prediction Models
The leave-one-out cross validation (LOOCV) method was used to assess the predictive
performance of each outcome. The mean absolute error (MAE), standard error (SE) and standard
deviation (SD) for the models built for social support and community integration; presence of
depressive symptoms; VRQoL and preference-based HRQoL are presented in Tables 5-12, 5-18,
5-24 and 5-30, respectively. In addition to the four variable selection methods (selected
multivariable regression, stepwise regression, initial CART and pruned CART), the initial
multivariable regression model and the baseline model were assessed for comparison. The
baseline model, with only the intercept, is the worst possible model. First, the model with the
lowest MAE was selected, and all plausible models were selected if it was within one SE from
the lowest MAE. Of all plausible models, the most promising model was determined based on
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the model with the lowest number of variables selected. This procedure for selecting the most
promising model was followed by the methodology outlined by Hastie et al. (2008)128.

5.6 Results for Each Patient-Reported Outcome
5.6.1 Social Support and Community Integration
Recall, that the Community Integration Questionnaire (CIQ) score was used to measure social
support and community integration on a scale from 0 to 29, in which a higher score represents
complete community integration and a higher level of social support. In our study population, the
average CIQ total score was 17.9±5.0, with a minimum average score of two and maximum of
28. Thus, majority of the patients had moderate social support and community integration.

5.6.1.1

Unadjusted Effects of Social Support and Community Integration

The bivariate analysis for social support and community integration with the demographic
variables is presented in Table 5-7, and for clinical variables it is presented in Table 5-8. The
following five demographic variables were significantly associated with social support and
community integration: age (p < 0.0001), sex (p < 0.0001), income (p < 0.0001), living
arrangement (p<0.0001), and use of mobility aid (p < 0.0001). On average, for every year
increase in age, the expected social support and community integration decreases by 0.17±0.03
(95% CI = -0.22 to -0.11). On average, males are expected to obtain a lower social support and
community integration than females (-3.18±0.61, 95% CI = -4.39 to -1.97). Patients with an
income between $25 000 to $50 000 (2.17±0.76, 95% CI = 0.66 to 3.67) and greater than $50
000 (2.95±0.77, 95% CI = 1.44 to 4.47), on average, are expected to obtain social support and
community integration that is greater than patients with income less than $25 000. On average,
patients living at home with others (-1.97±0.67, 95% CI = -3.30 to -0.65) and living in a
nursing/retirement home (-9.26±2.48, 95% CI = -14.15 to -4.38), are expected to obtain social
support and community integration that is lower than patients living at home alone. Patients
using a mobility aid, on average, are expected to obtain social support and community
integration that is lower than patients who do not use a mobility aid (-4.96±0.95, 95% CI = -6.84
to -3.09).
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The only clinical variable that was found to be significantly associated with social support and
community integration was moderate visual acuity loss (p = 0.01). On average, patients with
moderate visual acuity loss are expected to obtain social support and community integration that
is lower than patients with mild visual acuity loss (-2.23±0.89, 95% CI = -3.98 to -0.47).

5.6.1.2

Adjusted Effects Social Support and Community Integration

The estimated coefficients and p-values from the multivariable linear regression analysis with
social support and community integration as the dependent variable are presented in Table 5-9.
The five variables that were found to be significant with social support and community
integration are: age (p < 0.0001), sex (p < 0.0001), income (p < 0.0001), living arrangement (p <
0.0001) and use of mobility aid (p = 0.003). Adjusting for all predictor variables, for every year
increase in age, on average the expected social support and community integration decreases by
0.15±0.03 (95% CI= -0.21 to -0.09). On average, males are expected to obtain a lower social
support and community integration than females (-3.28±0.56, 95% CI= -4.38 to -2.18). Patients
with an income greater than $50 000, on average, are expected to obtain social support and
community integration that is greater than patients with income less than $25 000 (3.07±0.66,
95% CI= 1.77 to 4.37). Patients living at home with others (-2.58±0.59, 95% CI=-3.75 to -1.41)
and in nursing home or retirement home (-7.92±2.12, 95% CI= -12.09 to -3.74), on average, are
expected to obtain social support and community integration that is lower than patients who are
living at home alone. Patients using a mobility aid, on average, are expected to obtain social
support and community integration that is lower than patients who do not use a mobility aid (2.63±0.87, 95% CI= -4.34 to -0.92).
No clinical variables were found to be significantly associated with the CIQ score. When
controlling for all variables, age, sex, living arrangement and use of mobility aid had a negative
relationship with social support and community integration, and income had a positive
relationship. The overall model was significant (p < 0.0001), with a generalized R-squared of
0.42, suggesting that 42% of the variance in CIQ score is explained by this multivariable
regression model.
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5.6.1.3

Stepwise Regression for Social Support and Community
Integration

The results from stepwise regression analysis by AIC for social support and community
integration is presented in Table 5-10. The initial model for social support and community
integration consisted of the 13 predictor variables and had an AIC value of 706.19. The final
model with the lowest AIC value of 690.61, consisted of the following five predictor variables:
age, sex, income, living arrangement and use of mobility aid.

5.6.1.4

Regression Tree for Social Support and Community Integration

The initial regression tree of social support and community integration is presented in Figure 5-1,
where the data were split (root node) using the variable ‘use of mobility aid’ and the final split
(leaf node) contained the predicted score obtained from the CIQ, ranging from 0 to 29. For
example, a patient who does not use mobility aid, is a male and is not ³ 62 years of age, has a
predicted score of 21 (range = 0 to 29). The initial regression tree has 12 nodes, whereas the
pruned tree in Figure 5-2 has only three nodes.

Figure 5-1. Initial regression tree for social support and community integration
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Figure 5-2. Pruned regression tree for social support and community integration

5.6.1.5

Variable Selection for Social Support and Community Integration

The selected variables from multivariable regression, stepwise regression by AIC, initial and
pruned CART analyses for predicting social support and community integration are presented in
Table 5-11. Eight variables were selected from the initial CART analysis, five variables were
selected from multivariable and stepwise regression by AIC and three variables were selected
from the pruned CART analysis. Age, sex and use of mobility aid were selected from all four
methods. Income and living arrangement were selected from two of the four methods. Education,
number of comorbidities, number of ocular conditions and number of ocular procedures were not
selected from any of the methods. Thus, the main predictor variables explaining patients social
support and community integration among our patient populations seems to be age, sex and use
of mobility aids.

5.6.1.6

Model Assessments for Social Support and Community
Integration

The model with the lowest MAE for the social support and community integration outcome is
stepwise regression model by AIC, with a MAE of 3.21. The plausible models are the models
with a MAE of 3.37 or less, which include: initial multivariable regression model and selected
multivariable regression model. From Table 5-12, of the plausible models, the model with the
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lowest number of predictor variables is the selected multivariable and stepwise regression model.
Therefore, the most promising predictor variables of social support and community integration
are presented in the model below:
Social support and community integration = α + β1 (age) + β2 (sex) + β3 (income) + β4
(living arrangement) + β5 (use of mobility aid)

5.6.2 Presence of Depressive Symptoms
Recall, that the Patient Health Quesionnaire-9 (PHQ-9) total score was dichotomized as ‘no
depressive symptoms’ and ‘some depressive symptoms’ (refer to Section 4.5.2). Among the
study population, about 79% reported having no depressive symptoms. In other words, on the
original PHQ-9 scale (score range: 0 to 27), 79% of the patients reported a score of four or less.

5.6.2.1

Unadjusted Effects of the Presence of Depressive Symptoms

The bivariate analysis for the presence of depressive symptoms with the demographic variables
is presented in Table 5-13, and for clinical variables it is presented in Table 5-14. The following
four demographic variables were significantly associated with the presence of depressive
symptoms: income (p = 0.04), education (p < 0.0001), living arrangement (p = 0.04), and use of
mobility aid (p < 0.0001). Patients with an income greater than $50 000 (OR = 0.43, 95% CI =
0.19 to 0.96), on average, were less likely to report having depressive symptoms than patients
with income less than $25 000. On average, patients who completed more than high school were
less likely to report having depressive symptoms than patients who completed high school or less
(OR = 0.50, 95% CI = 0.27 to 0.93). Patients who used mobility aid, on average, were more
likely to report having depressive symptoms than patients who did not use mobility aid (OR =
3.31, 95% CI = 1.46 to 7.53).
Initial treatment (p < 0.0001) was the only clinical variable that showed significant association
with the presence of depressive symptoms.

5.6.2.2

Adjusted Effects of the Presence of Depressive Symptoms

The estimated odds ratio and p-values from the multivariable logistic regression analysis with the
presence of depressive symptoms as the dependent variable, are presented in Table 5-15. Two
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variables were significantly associated with the presence of depressive symptoms: use of
mobility aid (p = 0.006) and initial treatment (p = 0.01). Patients who used a mobility aid were
more likely to report having depressive symptoms than patients who did not use a mobility aid
(OR=4.37, 95% CI=1.59 to 12.05). Patients who had selective laser trabeculoplasty as their
initial treatment (OR=3.52, 95% CI=1.42 to 8.75) and no initial treatment (OR=3.24, 95%
CI=1.02 to 10.27) were more likely to report having depressive symptoms than patients who had
medication as their initial treatment.
The generalized R-squared is not interpreted the same way for logistic regression, as it is in
linear regression. Rather, the pseudo R-squared measure is used in logistic regression and it is
defined as the following:
1−

log 25D_25ℎ33i 3j 6ℎ_ jk22 H3i_2, l56ℎ 6ℎ_ 5I6_Rm_B6
log 25D_25ℎ33i 3j 6ℎ_ H3i_2 l56ℎ 3I2# 6ℎ_ 5I6_Rm_B6

The pseudo R-squared corresponds to a proportional reduction in the error variance181. The
overall model for the presence of depressive symptoms was significant (p = 0.04), with a pseudo
R-squared of 0.16.

5.6.2.3

Stepwise Regression for the Presence of Depressive Symptoms

The stepwise regression analysis by AIC for the presence of depressive symptoms is presented in
Table 5-16. The initial model for presence of depressive symptoms consisted of the 13 predictor
variables and had an AIC value of 258.39. The final model with the lowest AIC value of 247.71,
consisted of the following seven predictor variables: age, sex, education, living arrangement, use
of mobility aid, number of comorbidities and initial treatment.

5.6.2.4

Classification Tree for Presence of Depressive Symptoms

The initial classification tree for presence of depressive symptoms is presented in Figure 5-3,
where the data were split (root node) using the variable ‘use of mobility aid’ and the final split
(leaf node) contained the predicted probability of having depressive symptoms (0 = no
depressive symptoms). For example, a patient who does not use mobility aids, who’s initial
treatment is medication, is ³ 62 years of age and time since diagnosis is < 138 months, was
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predicted to have a 0.077 probability of having depressive symptoms. The initial classification
tree has 12 nodes, and pruning the tree resulted in zero splits.

Figure 5-3.Initial classification tree for presence of depressive symptoms

5.6.2.5

Variable Selection for Presence of Depressive Symptoms

The selected variables from multivariable regression, stepwise regression by AIC, initial and
pruned CART analyses for predicting the presence of depressive symptoms is presented in Table
5-17. Eight variables were selected from stepwise regression and seven from the initial CART
analysis. Two variables were selected from multivariable regression analysis. No variables were
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selected by the pruned CART analysis. Initial treatment was selected from all four methods. Use
of mobility and initial treatment were selected from three of the four methods. BCVA, number of
ocular conditions, number of ocular procedures and glaucoma stage were not selected from any
of the methods. Thus, the main predictor variables explaining the presence of depressive
symptoms among our patient population were use of mobility aids and initial treatment.

5.6.2.6

Model Assessment for the Presence of Depressive Symptoms

The model with the lowest MAE for the presence of depressive symptoms is stepwise regression
model by AIC, with a MAE of 0.30. The plausible models are the models with a MAE of 0.32 or
less, which include: initial multivariable regression model, selected multivariable regression
model and initial classification tree. From Table 5-18, of the plausible models, the model with
the lowest number of predictor variables is the selected multivariable regression model.
Therefore, the most promising predictor variables for the presence of depressive symptoms are
presented in the model below:
Depressive symptoms = α + β1 (use of mobility aid) + β2 (initial treatment)

5.6.3 Vision-Related Quality of Life
Recall, that the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was used
to assess the vision-related quality of life (VRQoL) among the study population. The overall
composite score ranged from 0 to 100, where 100 is the best possible score. On average, the
patients reported a composite score of 88.7±12.4, with a minimum average score of 9.8 and
maximum of 100. Thus, majority of the patients had a fairly high VRQoL.

5.6.3.1

Unadjusted Effects of Vision-Related Quality of Life

The bivariate analysis for VRQoL with the demographic variables are presented in Table 5-19,
and for clinical variables it is presented in Table 5-20. The two demographic variables associated
with VRQoL were income (p = 0.006) and use of mobility aids (p < 0.0001). On average,
patients with an income greater than $50 000, are expected to obtain VRQoL that is greater than
patients with income less than $25 000 (5.19±1.89, 95% CI = 1.48 to 8.91). Patients who use
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mobility aids, on average, are expected to obtain VRQoL that is less than patients who do not use
a mobility aids (-11.49±2.37, 95% CI = -16.16 to -6.81).
The two clinical variables associated with VRQoL were BCVA in the worse-seeing eye (p <
0.0001) and number of ocular conditions (p = 0.004). On average, patients with moderate visual
acuity loss (-9.00±1.91, 95% CI = -12.76 to -5.25) and legal blindness (-18.44±2.03, 95% CI = 22.43 to -14.45), are expected to obtain VRQoL that is less than patients with mild visual acuity.
On average, for each increase in number of ocular conditions, the expected VRQoL decreases by
2.05±0.71 (95% CI = -3.44 to -0.65).

5.6.3.2

Adjusted Effects of Vision-Related Quality of Life

The estimated coefficients and p-values from the multivariable linear regression analysis with
VRQoL as the dependent variable is presented in Table 5-21. The following three demographic
and one clinical variables were significantly associated with VRQoL: income (p = 0.01), living
arrangement (p = 0.03), use of mobility aid (p < 0.0001) and BCVA in the worse-seeing eye (p <
0.0001). When controlling for all variables, living arrangement, use of mobility aids, BCVA in
the worse-seeing eye had a negative relationship with VRQoL and income had a positive
relationship.
Patients with an income greater than $50 000, on average are expected to obtain VRQoL that is
greater than patients income less than $25 000 (3.99±1.63, 95% CI= 0.78 to 7.19). Patients living
in a nursing or retirement home, on average, are expected to obtain VRQoL that is lower than
patients living at home alone (-22.49±5.24, 95% CI= -32.82 to -12.16). Patients using mobility
aids, on average, are expected to obtain VRQoL that is lower than patients not using mobility
aids (-7.62±2.15, 95% CI= -11.85 to -3.39). Patients with a moderate visual acuity loss (8.20±1.92, 95% CI= -11.97 to -4.42) and legal blindness (-17.03±2.02, 95% CI= -21.02 to 13.05), on average, are expected to obtain VRQoL that is lower than patients with mild visual
acuity loss.
The overall model was significant (p < 0.0001), with a generalized R-squared of 0.40, suggesting
that 40% of the variance in NEI VFQ-25 score is explained by this multivariable regression
model.
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5.6.3.3

Stepwise Regression for Vision-Related Quality of Life

The stepwise regression analysis by AIC for the presence of VRQoL is presented in Table 5-22.
The initial model for VRQoL consisted of the 13 predictor variables and had an AIC value of
1167.55. The final model with the lowest AIC value of 1152.89, consisted of the following five
predictor variables: income, living arrangement, use of mobility aid, BCVA in the worse-seeing
eye and number of ocular conditions.

5.6.3.4

Regression Tree for Vision-Related Quality of Life

The initial regression tree of VRQoL is presented in Figure 5-4, where the data were split (root
node) using the variable ‘BCVA’ and the final split (leaf node) contained the predicted NEI
VFQ-25 score ranging from 0 to 100. For example, a patient whose BCVA is categorized as
moderate visual acuity loss or legal blindness and uses mobility aid, has a predicted score of 67
(range = 0 to 100). The initial regression tree has five nodes, whereas the pruned tree in Figure 55 has only one node.

Figure 5-4. Initial regression tree for vision-related quality of life
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Figure 5-5. Pruned regression tree for vision-related quality of life

5.6.3.5

Variable Selection for Vision-Related Quality of Life

The selected variables from multivariable regression, stepwise regression by AIC, initial and
pruned CART analyses for predicting VRQoL is presented in Table 5-23. Five variables were
selected from stepwise regression and the initial CART analysis. Four variables were selected
from multivariable regression and one variable was selected from the pruned CART analysis.
BCVA was selected from all four methods. Income and use of mobility aids were selected from
three of the four methods. Sex, education, number of comorbidities, number of ocular
procedures, time since diagnosis and initial treatment were not selected from any of the methods.
The main predictor variable explaining VRQoL is BCVA in the worse-seeing eye.

5.6.3.6

Model Assessments for Vision-Related Quality of Life

The model with the lowest MAE is the pruned regression tree, with a MAE of 6.77. The
plausible models are the models with a MAE of 7.33 or less, which include: initial multivariable
regression model, selected multivariable regression model, stepwise regression model and initial
regression tree. From Table 5-24, of the plausible models, the model with the lowest number of
predictor variables is the pruned regression tree. Therefore, the most promising predictor
variables of VRQoL is presented in the mode below:
VRQoL = α + β1 (BCVA in the worse-seeing eye)

5.6.4 Preference-Based Health-Related Quality of Life
Recall, that the Time Trade-Off (TTO) technique was used to measure the patients’ preferencebased HRQoL and the utility value was dichotomized to “not willing to give up any years of life”
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and “willing to give up some years of life” (refer to Section 4.5.4). Among the study population,
about 71% were not willing to give up any years of life for perfect vision. Thus, majority of the
patients had a high preference-based HRQoL.

5.6.4.1

Unadjusted Effects of Preference-Based Health-Related Quality
of Life

The bivariate analysis for preference-based HRQoL with the demographic variables are
presented in Table 5-25, and for clinical variables in Table 5-26. One demographic and two
clinical variables were significantly associated with preference-based HRQoL: education (p <
0.0001), legal blindness (p = 0.009) and number of ocular conditions (p = 0.02). Patients with
legal blindness, on average, were more willing to give up some years of like for perfect vision
than patients with mild visual acuity loss (OR = 2.81, 95% CI = 1.29 to 6.14). On average,
patients were more willing to give up some years of life for perfect vision with increasing
number of ocular conditions (OR = 1.37, 95% CI = 1.06 to 1.76).

5.6.4.2

Adjusted Effects of Preference-Based Health-Related Quality of
Life

The estimated odds ratio and p-values from the multivariable logistic regression analysis with
preference-based HRQoL as the dependent variable is presented in Table 5-27. Two clinical
variables were found to be significantly associated with preference-based HRQoL: BCVA in the
worse-seeing eye (p = 0.01) and number of ocular conditions (p = 0.04). No demographic
variables were found to be significantly associated.
Patients with legal blindness were more willing to give up some years of life for perfect vision
than patients with mild visual acuity loss (OR=3.10, 95% CI= 1.27 to 7.57). Patients were more
willing to give up some years of life for perfect vision with increasing number of ocular
conditions (OR=1.35, 95% CI= 0.60 to 3.04).
The overall model was not significant (p = 0.24), with a pseudo R-squared of 0.09.
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5.6.4.3

Stepwise Regression for Preference-Based Health-Related
Quality of Life

The stepwise regression analysis by AIC for the presence of preference-based HRQoL is
presented in Table 5-28. The initial model for preference-based HRQoL consisted of the 13
predictor variables and had an AIC value of 312.88. The final model with the lowest AIC value
of 294.68, consisted of the following four predictor variables: age, education, BCVA worseseeing eye and number of ocular conditions.

5.6.4.4

Classification Tree for Preference-Based Health-Related Quality
of Life

The initial classification tree for preference-based HRQoL is presented in Figure 5-6, where the
data were split (root node) using the variable ‘age’ and the final split (leaf node) contained the
predicted probability of giving up any years of life for perfect vision (0 = not willing to give up
any years of life). For example, a patient who is ³ 76 years of age, BCVA is categorized as mild
VA loss and has < 2.5 ocular procedures, is predicted to have a 0.11 probability of giving up
years of life for perfect vision. The initial classification tree has 15 nodes, and pruning the tree
resulted in zero splits.
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Figure 5-6. Initial classification tree for preference-based Health-Related quality of life

5.6.4.5

Variable Selection for Preference-Based Health-Related Quality
of Life

The selected variables from multivariable regression, stepwise regression by AIC, initial and
pruned CART analyses for predicting preference-based HRQoL is presented in Table 5-29. Ten
variables were selected from the initial CART analysis. Four variables were selected from the
stepwise regression analysis. Two variables were selected from the multivariable regression
analysis. No variables were selected from the pruned CART analysis. BCVA and number of
ocular conditions were selected from two of the four methods. Sex, income and living
arrangement were not selected from any of the methods. The main predictor variables explaining
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the patients’ preference-based HRQoL seems to be BCVA in worse-seeing eye and number of
ocular conditions.

5.6.4.6

Model Assessments for Preference-Based Health-Related
Quality of Life

The model assessment results for preference-based HRQoL is presented in Table 5-30. The
model with the lowest MAE for preference-based HRQoL is initial classification tree, with a
MAE of 0.36. The plausible models are the models with a MAE of 0.38 or less, which only
included the initial classification tree. However, the initial classification tree is fairly complex
with 10 predictor variables and may be overfitting, thus this model needs further assessment:
Preference-based HRQoL = α + β1 (age) + β2 (education) + β3 (use of mobility aid) + β4
(BCVA in the worse-seeing eye) + β5 (number of comorbidities) + β6 (number of ocular
conditions) + β7 (number of ocular procedures) + β8 (glaucoma stage) + β9 (time since
diagnosis) + β10 (initial treatment)
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Table 5-1. Demographic characteristics of the study population (N = 250)
Demographic Variables
Age (years)
Race
Caucasian
East Asian
Black
First Nations
Other
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid

Mean (SD) or Number of Patients (%)
72.9 (10.2)
199 (79.6)
3 (1.2)
4 (1.6)
3 (1.2)
41 (16.4)
87 (37.5)
73 (31.5)
72 (31.0)
122 (48.8)
128 (51.2)
73 (29.2)
173 (69.2)
4 (1.6)
222 (88.8)
28 (11.2)
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Table 5-2. Clinical characteristics of the study population (N = 250)
Clinical Variables

Mean (SD) or Number of Patients (%)

Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

181 (72.4)
37 (14.8)
32 (12.8)
1.6 (1.4)
2.1 (1.1)
1.1 (1.0)
82 (32.8)
65 (26.0)
65 (26.0)
38 (15.2)
100.7 (74.5)
180 (72.0)
43 (17.2)
27 (10.8)

Table 5-3. Pre- and post-imputed income values
Missing Variable
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000

Pre-imputed income values
Number of patients (%)

Post-imputed income values
Number of patients (%)

87 (37.5)
73 (31.5)
72 (31.0)
N = 232

99 (39.6)
75 (30.0)
76 (30.4)
N = 250
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Table 5-4. Pearson correlation coefficient for the association between pairs of continuous
predictor variables
Age
Age
Number of
Comorbidities
Number of
Ocular
Conditions
Number of
Ocular
Procedures
Time Since
Diagnosis

Number of
Number of
Comorbidities Ocular
Conditions

Number of Time
Ocular
Since
Procedures Diagnosis

1.00
0.16

1.00

0.02

-0.01

1.00

0.26

0.03

0.16

1.00

0.004

0.05

0.07

0.21

1.00

Table 5-5. Chi-square tests (p-value) for the association between pairs of categorical

Best Corrected Visual
Acuity

Glaucoma Stage

Initial Treatment

Education
0.22
0.49

Use of Mobility Aid

0.001

Living Arrangement

Sex
Income
Education
Living
Arrangement
Use of Mobility Aid
Best Corrected
Visual Acuity
Glaucoma Stage
Initial Treatment

Income

Sex

predictor variables

0.02
0.13
0.06

0.46
0.05
0.03
0.68

0.14
0.22
0.21
0.84

0.10
0.62
0.85
0.46

0.27
0.96
0.89
0.81

0.02

0.79
0.002

0.56
0.52
<0.0001
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Table 5-6. Results of associations between continuous and categorical predictor variables
Variable

Age

Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid

Number of
Ocular
Procedures
p-value
mean (SD)
0.89
1.06 (1.0)
1.08 (1.1)
0.85
1.11 (0.9)
1.05 (1.0)
1.03 (1.1)
0.83
1.08 (1.0)
1.05 (1.0)
0.67
1.14 (1.0)
1.05 (1.0)
0.75 (1.0)
0.31

Time Since
Diagnosis

p-value
mean (SD)
0.97
72.97 (9.6)
72.92 (11.1)
0.03
75.01 (10.0)
71.15 (9.2)
72.04 (11.1)
0.15
73.89 (10.7)
72.05 (9.8)
0.0003
76.82 (9.6)
71.22 (9.8)
77.00 (18.7)
<0.0001

Number of
Number of
Comorbidities Ocular
Conditions
p-value
p-value
mean (SD)
mean (SD)
0.01
0.08
1.77 (1.4)
2.05 (1.0)
1.33 (1.3)
2.29 (1.2)
0.75
0.46
1.62 (1.3)
2.19 (1.3)
1.67 (1.6)
2.01 (0.9)
1.50 (1.4)
2.21 (1.0)
0.33
0.96
1.51 (1.4)
2.15 (1.1)
1.68 (1.4)
2.14 (1.1)
0.94
0.92
1.63 (1.3)
2.18 (1.1)
1.57 (1.4)
2.13 (1.1)
1.75 (1.3)
2.00 (1.2)
0.23
0.20

Does not use mobility aid
Uses mobility aid
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Glaucoma Stage
Suspect
Early
Moderate
Severe
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

71.98 (10.1)
80.61 (8.0)
0.03
71.90 (10.5)
76.30 (9.4)
75.03 (8.3)
0.0009
69.45 (11.1)
75.23 (9.5)
73.35 (8.5)
75.90 (10.4)
0.17
73.57 (10.1)
72.40 (9.2)
69.70 (12.3)

1.56 (1.4)
1.89 (1.5)
0.36
1.61 (1.4)
1.78 (1.2)
1.31 (1.5)
0.47
1.59 (1.3)
1.72 (1.6)
1.66 (1.4)
1.23 (1.2)
0.12
1.50 (1.4)
1.70 (1.6)
2.07 (1.1)

1.05 (1.0)
1.25 (0.9)
0.17
0.99 (1.0)
1.24 (1.0)
1.28 (1.2)
0.04
0.84 (0.8)
1.26 (1.1)
1.03 (1.0)
1.29 (1.2)
0.001
1.21 (1.1)
0.67 (0.8)
0.74 (0.8)

99.63 (74.7)
109.82 (74.1)
0.16
100.60 (71.3)
85.30 (66.0)
119.63 (96.8)
0.07
83.24 (63.5)
106.55 (94.2)
109.23 (63.5)
114.24 (72.3)
0.0002
111.50 (77.3)
86.54 (58.6)
51.93 (54.2)

2.11 (1.1)
2.39 (1.2)
0.006
2.01 (1.0)
2.43 (1.4)
2.56 (1.1)
0.97
2.15 (1.1)
2.17 (1.1)
2.09 (1.0)
2.18 (1.2)
0.19
2.22 (1.1)
1.88 (1.1)
2.07 (1.0)

p-value
mean (SD)
0.13
94.88 (73.6)
109.61 (75.5)
0.88
98.54 (70.8)
100.17 (71.6)
104.28 (82.5)
0.11
93.09 (68.5)
108.09 (79.5)
0.91
101.77 (65.9)
100.71 (78.0)
85.50 (89.6)
0.50
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Table 5-7. Unadjusted effects of demographic variables with social support and community
integration
Demographic Variables
Age (years)
Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid

Coefficient
-0.17
Ref
-3.18
Ref
2.17
2.95
Ref
0.18
Ref
-1.97
-9.26
Ref
-4.96

P-value
<0.0001
<0.0001
<0.0001
<0.0001
0.005
<0.0001
0.62
0.78
<0.0001
0.004
<0.0001
<0.0001
<0.0001
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Table 5-8. Unadjusted effects of clinical variables with social support and community
integration
Clinical Variables
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

Coefficient
Ref
-2.23
-1.60
-0.08
-0.07
-0.33
Ref
-1.08
-0.50
-1.19
0.0002
Ref
0.39
1.67

P-Value
0.25
0.01
0.09
0.74
0.82
0.29
0.74
0.19
0.54
0.23
0.96
0.44
0.65
0.11
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Table 5-9. Adjusted effects for social support and community integration
Variables
Age (years)
Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

Coefficient
-0.15
Ref
-3.28
Ref
1.34
3.07
Ref
0.05
Ref
-2.58
-7.92
Ref
-2.63
Ref
-1.59
-0.76
-0.04
0.22
0.04
Ref
0.54
0.42
1.34
0.002
Ref
0.50
1.41

P-value
<0.0001
<0.0001
<0.0001
<0.0001
0.04
<0.0001
0.76
0.92
<0.0001
<0.0001
<0.0001
0.003
0.003
0.15
0.04
0.35
0.83
0.37
0.89
0.22
0.45
0.56
0.13
0.58
0.09
0.49
0.13
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Table 5-10. Stepwise regression analysis for social support and community integration
Model ID
1 (initial)
2
3
4
5
6
7
8
9

Eliminated Variable

AIC
706.19
702.25
699.72
697.72
695.73
693.83
692.05
690.99
690.61

Glaucoma Stage
Initial Treatment
Number of Comorbidities
Education
Time Since Diagnosis
Number of Ocular Procedures
Number of Ocular Conditions
Best Corrected Visual Acuity

X
13

Pruned Classification
and Regression Tree

Initial Treatment
No. of Selected Variables

Initial Classification
and Regression Tree

X
X
X
X
X
X
X
X
X
X
X
X

Stepwise Model
Selection by AIC

Age
Sex
Income
Education
Living Arrangement
Use of Mobility Aid
BCVA in Worse-Seeing Eye
No. of Comorbidities
No. of Ocular Conditions
No. of Ocular Procedures
Glaucoma Stage
Time Since Diagnosis

Selected Multivariable
Regression Model

Initial Multivariable
Regression Model

Table 5-11. Variable selection for social support and community integration

X
X
X

X
X
X

X
X
X

X
X

X
X

X
X

X
X
X

X

X
X
5

5

8

3
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Table 5-12. Model assessments from leave-one-out cross validation for social support and

Initial Multivariable
Regression Model

Selected Multivariable
Regression Model

Stepwise Regression
Model by AIC

Initial Classification
and Regression Tree

Pruned Classification
and Regression Tree

Mean Absolute Error
Standard Error
Standard Deviation

Baseline Model
(intercept only)

community integration models

3.99
0.19
3.02

3.32
0.16
2.52

3.23
0.15
2.40

3.21
0.16
2.45

3.87
0.20
3.11

3.90
0.19
3.02

Table 5-13. Unadjusted effects of demographic variables for the presence of depressive
symptoms
Demographic Variables
Age (years)
Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid

Odds Ratio
0.99
Ref
0.52
Ref
0.69
0.43
Ref
0.50
Ref
0.58
2.65
Ref
3.31

P-value
0.51
0.31
0.05
0.04
0.32
0.04
<0.0001
0.03
0.04
0.10
0.35
<0.0001
0.004
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Table 5-14. Unadjusted effects of clinical variables for the presence of depressive symptoms
Clinical Variables
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

Odds Ratio

P-Value
0.47

Ref
1.76
1.17
0.91
1.14
1.00
Ref
0.44
0.75
0.73
1.00
Ref
2.08
2.40

0.16
0.74
0.40
0.37
0.95
0.74
0.06
0.46
0.50
0.70
<0.0001
0.06
0.05
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Table 5-15. Adjusted effects for the presence of depressive symptoms
Variables
Age (years)
Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

Odds Ratio
0.97
Ref
0.49
Ref
0.82
0.57
Ref
0.60
Ref
0.59
4.68
Ref
4.37
Ref
1.81
0.83
0.83
1.20
1.13
Ref
0.60
1.01
1.09
1.00
Ref
3.52
3.24

P-value
0.07
0.09
0.08
0.15
0.64
0.23
0.09
0.16
0.41
0.17
0.18
0.006
0.004
0.80
0.23
0.73
0.18
0.26
0.52
0.71
0.31
0.99
0.89
0.15
0.01
0.007
0.046
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Table 5-16. Stepwise regression for the presence of depressive symptoms
Model ID
1 (initial)
2
3
4
5
6

Eliminated Variable
None
Glaucoma Stage
Income
Number of Ocular Procedures
Best Corrected Visual Acuity
Number of Ocular Conditions

AIC
258.39
253.84
251.44
249.69
248.03
247.71

Age
Sex
Income
Education
Living Arrangement
Use of Mobility Aid
BCVA in Worse-Seeing Eye
No. of Comorbidities
No. of Ocular Conditions
No. of Ocular Procedures
Glaucoma Stage
Time Since Diagnosis
Initial Treatment
No. of Selected Variables

X
X
X
X
X
X
X
X
X
X
X
X
X
13

X
X

X

X
2

X
X
X

Pruned Classification
and Regression Tree

Initial Classification
and Regression Tree

Stepwise Model
Selection by AIC

Selected Multivariable
Regression Model

Initial Multivariable
Regression Model

Table 5-17. Variable selection results for presence of depressive symptoms

X
X
X
X

X

X

X
X
8

X
X
7

0
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Table 5-18. Model assessments from leave-one-out cross validation for presence of

Initial Multivariable
Regression Model

Selected Multivariable
Regression Model

Stepwise Regression
Model by AIC

Initial Classification
and Regression Tree

Pruned Classification
and Regression Tree

Mean Absolute Error
Standard Error
Standard Deviation

Baseline Model
(Intercept only)

depressive symptoms

0.34
0.02
0.24

0.31
0.02
0.27

0.32
0.02
0.25

0.30
0.02
0.26

0.32
0.02
0.30

0.34
0.02
0.24

Table 5-19. Unadjusted effects of demographic variables for vision-related quality of life
Demographic Variables
Age (years)
Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid

Coefficient
-0.07
Ref
0.08
Ref
2.28
5.19
Ref
1.58
Ref
-0.58
-23.23
Ref
-11.49

P-value
0.35
0.88
0.96
0.006
0.23
0.006
0.114
0.31
0.12
0.73
<0.0001
<0.0001
<0.0001
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Table 5-20. Unadjusted effects of clinical variables for vision-related quality of life
Clinical Variables
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

Coefficient

P-Value
<0.0001

Ref
-9.00
-18.44
0.43
-2.05
-0.59
Ref
1.56
0.59
-3.61
0.006
Ref
0.46
-2.86

<0.0001
<0.0001
0.45
0.004
0.45
0.225
0.45
0.77
0.14
0.60
0.36
0.83
0.26
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Table 5-21. Adjusted effects for vision-related quality of life
Variables
Age (years)
Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

Coefficient
0.07
Ref
1.04
Ref
0.87
3.99
Ref
0.40
Ref
-1.29
-22.49
Ref
-7.62
Ref
-8.20
-17.03
0.44
-1.02
-0.27
Ref
1.13
0.16
0.99
0.006
Ref
-0.64
-2.55

P-value
0.33
0.45
0.45
0.01
0.59
0.02
0.64
0.76
0.03
0.38
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.36
0.09
0.67
0.88
0.52
0.93
0.65
0.50
0.20
0.72
0.27
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Table 5-22. Stepwise regression analysis for vision-related quality of life
Model ID
1 (initial)
2
3
4
5
6
7
8
9

Eliminated Variable
None
Glaucoma Stage
Initial Treatment
Number of Ocular Procedures
Education
Number of Comorbidities
Sex
Time Since Diagnosis
Age

AIC
1167.55
1162.04
1159.97
1157.98
1156.01
1154.71
1153.45
1153.03
1152.89

Age
Sex
Income
Education
Living Arrangement
Use of Mobility Aid
BCVA in Worse-Seeing Eye
No. of Comorbidities
No. of Ocular Conditions
No. of Ocular Procedures
Glaucoma Stage
Time Since Diagnosis

X
X
X
X
X
X
X
X
X
X
X
X

Initial Treatment
No. of Selected Variables

X
13

Pruned Classification
and Regression Tree

Initial Classification
and Regression Tree

Stepwise Model
Selection by AIC

Selected Multivariable
Regression Model

Initial Multivariable
Regression Model

Table 5-23. Variable selection for vision-related quality of life

X
X

X

X

X
X
X

X
X
X

X
X

X

X
X

4

5

5

1
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Table 5-24. Model assessments from leave-one-out cross validation for vision-related

Initial Multivariable
Regression Model

Selected Multivariable
Regression Model

Stepwise Regression
Model by AIC

Initial Classification
and Regression Tree

Pruned Classification
and Regression Tree

Mean Absolute Error
Standard Error
Standard Deviation

Baseline Model
(Intercept only)

quality of life

7.73
0.61
9.69

7.23
0.53
8.32

6.86
0.52
8.14

6.95
0.51
8.07

7.25
0.58
9.12

6.77
0.56
8.83

Table 5-25. Unadjusted effects of demographic variables with preference-based HRQoL
Demographic Variables
Age (years)
Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid

Odds Ratio
0.98
Ref
1.32
Ref
0.75
0.76
Ref
1.54
Ref
1.58
1.10
Ref
0.62

P-value
0.96
0.96
0.33
0.42
0.40
0.44
<0.0001
0.13
0.23
0.16
0.94
0.83
0.32
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Table 5-26. Unadjusted effects of clinical variables with preference-based HRQoL
Clinical Variables
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

Coefficient

P-Value
0.22

Ref
1.70
2.81
0.87
1.37
1.01
Ref
1.00
1.20
1.03
1.00
Ref
1.72
0.97

0.17
0.009
0.19
0.02
0.97
0.16
0.98
0.61
0.95
0.78
0.27

0.95
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Table 5-27. Adjusted effects for preference-based HRQoL
Variables
Age (years)
Sex
Female
Male
Income
Less than $25 000
$25 000 to $50 000
Greater than $50 000
Education
Completed high school or less
Completed more than high school
Living Arrangement
Home alone
Home with others
Nursing/Retirement home
Use of Mobility Aid
Does not use mobility aid
Uses mobility aid
Best Corrected Visual Acuity
Mild visual acuity loss
Moderate visual acuity loss
Legal blindness
Number of Comorbidities
Number of Ocular Conditions
Number of Ocular Procedures
Glaucoma Stage
Suspect
Early
Moderate
Severe
Time Since Diagnosis (months)
Initial Treatment
Medication
Selective Laser Trabeculoplasty
No initial treatment

Odds Ratio
0.98
Ref
1.14
Ref
0.72
0.64
Ref
1.50
Ref
1.53
1.30
Ref
0.48
Ref
2.11
3.10
0.88
1.35
1.02
Ref
1.09
1.35
0.90
1.00
Ref
1.98
1.19

P-value
0.28
0.65
0.69
0.24
0.40
0.28
0.20
0.19
0.32
0.24
0.84
0.19
0.20
0.01
0.09
0.01
0.27
0.04
0.91
0.83
0.85
0.46
0.84
0.95
0.39
0.09
0.76
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Table 5-28. Stepwise regression analysis for preference-based HRQoL
Model ID
1 (initial)
2
3
4
5
6
7
8
9
10

Eliminated Variable
None
Glaucoma Stage
Income
Living Arrangement
Time Since Diagnosis
Number of Ocular Procedures
Sex
Use of Mobility Aid
Number of Comorbidities
Initial Treatment

AIC
312.88
307.74
305.19
302.46
300.46
298.47
296.56
295.64
295.11
294.68

Initial Treatment
No. of Selected Variables

X
13

X

X

X

X

X

X

X

X

2

4

Pruned Classification
and Regression Tree

Initial Classification
and Regression Tree

X
X
X
X
X
X
X
X
X
X
X
X

Stepwise Model
Selection by AIC

Age
Sex
Income
Education
Living Arrangement
Use of Mobility Aid
BCVA in Worse-Seeing Eye
No. of Comorbidities
No. of Ocular Conditions
No. of Ocular Procedures
Glaucoma Stage
Time Since Diagnosis

Selected Multivariable
Regression Model

Initial Multivariable
Regression Model

Table 5-29. Variable selection results for predicting preference-based HRQoL

X
X
X
X
X
X
X
X
10

0

Initial Multivariable
Regression Model
Selected Multivariable
Regression Model
Stepwise Regression
Model by AIC
Initial Classification
and Regression Tree
Pruned Classification
and Regression Tree

Mean Absolute Error
Standard Error
Standard Deviation
Baseline Model
(Intercept only)

93

Table 5-30. Model assessments from leave-one-out cross validation for preference-based

HRQoL

0.42
0.01
0.19
0.41
0.02
0.24
0.41
0.01
0.21
0.40
0.01
0.22
0.36
0.02
0.31
0.42
0.01
0.19
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Chapter 6

6

Discussion

This chapter begins with a statement of the overall goal of our research study (Section 6.1).
Section 6.2 presents a summary of the study results. Following is the interpretation of the study
results coinciding with each study objective (Section 6.3). Next, the strengths and limitations
(Section 6.4) of the study are presented. The future directions are discussed in Section 6.5.
Lastly, the conclusions are presented in Section 6.6.

6.1

Overall Goal of Study

The overall goal of our research study was to identify predictor variables that are most strongly
associated with four PROs: social support and community integration; presence of depressive
symptoms; VRQoL; and preference-based HRQoL. This was accomplished through rigorous
methodologies including inferential statistics and machine learning techniques. Identifying
important drivers of PROs can support ophthalmologists to better manage and treat glaucoma
patients. In addition to the clinical importance of this study, the proposed methodology can be
used for future research. Our research study highlights rigorous methodology that goes beyond
interpreting results based on statistical significance.

6.2

Summary of Study Results

Overall, the patients in our study are satisfied with their care and treatment. Patients reported low
depressive symptoms, moderate social support and community integration, high VRQoL and
preference-based HRQoL.
The patients were spread across a wide age range between 40 and 93 years of age, with a mean
age of about 73 years old. Forty percent of the patients had an income lower than $25 000, and
about 49% completed high school or less, thus there was not much variability in income and
education levels. In terms of their clinical outcomes, about 72% experienced mild visual acuity
loss; thus, their visual functioning was not greatly debilitated. The time since diagnosis ranged
widely from one month to about 42 years, with an average time of about eight years. On average,
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the patients had about two other comorbidities and two other ocular conditions (excluding
glaucoma) and had about one prior ocular procedure performed.
In our patient population, use of mobility aids was a common predictor variable identified for
three of the PROs: social support and community integration, presence of depressive symptoms
and VRQoL. BCVA in the worse-seeing eye was a common predictor variable identified for
three of the PROs: social support and community integration, VRQoL and preference-based
HRQoL. Income and living arrangements were common predictor variables identified for social
support and community integration and VRQoL. Thus, across all PROs, clinical predictors that
are routinely collected (BCVA) during a typical comprehensive eye exam did not seem to have
as much of an influence as the variables that were not typically collected (use of mobility aids,
income and living arrangements).
Understanding the predictor variables of important PROs may help ophthalmologists identify
patients who are at a greater risk or who would most benefit from services that could improve
their disease management. For instance, if an ophthalmologist can identify a patient who may
need social support and who is unable to perform activities of daily living due to their glaucoma
progression, then ophthalmologists would consider referral of these patients for necessary
support and services. The developed models could help ophthalmologists be more aware of their
patients’ ocular and non-ocular needs. This is particularly important for this patient population,
since our study findings suggest that many of the factors that are driving PROs are not clinical.
Our results indicate that ensuring that the patient has an adequate support system and access to
services to help them adapt to loss of their visual functioning could have a larger impact on
improving PROs than providing clinical management alone. In addition, the results obtained can
be a guide for future ophthalmic research in assessing predictor variables of important PROs.
The developed models (refer to Section 5.6) may be a useful tool for ophthalmologists,
researchers, health economists and policy makers for better tailored glaucoma management.
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6.3

Interpretation of Study Results

6.3.1 Social Support and Community Integration
The first objective of our research study was to assess social support and community integration
as measured by the Community Integration Questionnaire (CIQ), and determine which clinical
and/or demographic variables impact the overall score.
Patients in our research study scored moderately high on the CIQ scale, with an average score of
17.9±5.0, representing moderate social support and community integration. In comparison, Hirsh
et al. (2011) conducted a cross-sectional study which included 751 adults with different physical
disabilities (spinal cord injury, multiple sclerosis, limb loss and muscular dystrophy), and
reported, on average, a similar total score of 17.1±5.1101. However, in comparison to our research
study, the participants from Hirsh et al.’s (2011) study were, on average, younger (50.9±13.5
years, range: 18 to 91) and a greater number had completed more than high school (84%)101.
Singh et al. (2015) conducted a study among 30 geriatric patients and reported a total score of
22.9±5.0, which is slightly higher than our study population109. On average, the study population
of Singh et al. (2015) was similar in age (73 years; range: 65 to 90) to our study population109.
However, the proportion of patients who were over 75 years of age was less (33%) than the
proportion in our study population (41%). Patients over 75 years of age may be less able to
participate in the community and lack social support than the younger patients. To our
knowledge, ophthalmology research and ophthalmic practice do not assess the patient’s social
support and community integration needs.
We found age, sex, income, living arrangement and use of mobility aids to be the most
promising predictor variables of social support and community integration. Specifically,
increasing age, being a male, and living at home with others or in a nursing/retirement home,
predicted lower social support and community integration. Income above $25 000 was predictive
of greater social support and community integration. Considering the absolute values of the
regression coefficients, living in a nursing or retirement home (b = -7.92) and having an income
greater than $50 000 (b = 3.07) are expected to have the strongest effects on the patient’s level of
social support and community integration. However, among our study population only 1.6% (n
= 4) were living in a nursing or retirement home. Our findings suggest that these patients are less
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functional within their community and need the support of others (i.e., spouse, family or
caregiver). For instance, patients who use mobility aids may require assistance to perform their
daily activities such as shopping and going to visit family and friends. To be more confident in
the results, a larger representation of patients living in a nursing or retirement home would be
required.
Overall, the moderate level of social support and community integration among our study
population was not surprising, since only a small proportion of our population had severe
glaucoma. This may reflect the practice pattern of the ophthalmologist who manages patients at
all stages of glaucoma and institutes care for preventing their disease from becoming advanced.
Thus, inclusion of more equal proportion of patients within each glaucoma stage and living
arrangement category may strengthen some associations.

6.3.2 Presence of Depressive Symptoms
The second objective of our research study was to assess the presence of depressive symptoms as
measured by the Patient Health Questionnaire-9 (PHQ-9), and determine which clinical and/or
demographic variables impact the presence or absence of depressive symptoms.
Depression has been reported to be higher in individuals with chronic illnesses and among
elderly people. Glaucoma is a chronic ocular disease that is most prevalent among elderly people
and due to the progression of vision loss, it is likely that patients experience depressive
symptoms182. Among our study population, about 21% reported having depressive symptoms.
Simon et al. (2008) used the Geriatric Depression Scale-15 and found that depression was more
prevalent with increasing glaucoma severity113. Although the majority of our study population
did not present with depressive symptoms, it is important to note that only about 15% of the
patients were diagnosed with severe glaucoma. Thus, having a study population that included a
greater number of patients with advanced disease may provide more accurate effect estimates.
Assessing depressive symptoms among glaucoma patients and identifying associated factors are
still important in providing better care to improve the patients’ HRQoL as knowledge of the
diagnosis itself and its treatment may be a source of depression for some patients.
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Our results suggest that use of mobility aids and initial treatment were the most promising
predictor variables of the presence of depressive symptoms. Patients who used mobility aids
were about four times more likely to report the presence of depressive symptoms than patients
who did not use mobility aids. It was predicted that medication use would be more burdensome
for the patient, due to the inconvenience of the medication regimen and well established reports
of poor patient compliance. However, our study results revealed that patients whose initial
treatment was selective laser trabeculoplasty (SLT), or who had no initiations of treatment, were
both more than about three times more likely to report having depressive symptoms compared to
patients whose initial treatment was medication. This study finding was surprising for a number
of reasons. Published studies have shown that both SLT and medication are known to be
effective in lowering IOP in patients, and literature supports SLT as an effective initial treatment
thus preventing, or delaying, the need for medical therapy183. Possible reasons for this finding
include: patients who did not receive medical management for glaucoma had, by chance, other
underlying causes for depressive symptoms; the patients who did not receive medical
management had protective factors against depression; patients whose initial treatment was
medication were more secure in the perception that they were actively participating in their
disease management; the need for chronic medical therapy is not as burdensome for some
patients as published studies have suggested; and lastly, a larger, more diverse sample size may
be required to accurately report on this finding.
To our knowledge no previous studies among glaucoma patients have used the PHQ-9 to assess
depressive symptoms. However, Wilson et al. (2002) did conduct a study using the Center for
Epidemiologic Studies Depression Scale and Composite International Diagnostic Interview Short
Form, among patients with glaucoma and without glaucoma182. Wilson et al., (2002) concluded
that patients with glaucoma did not report being more depressed than patients without
glaucoma182. On the other hand, a multicentre prospective case-control study reported that
patients with POAG had a higher prevalence of depression than the sex- and age-matched control
group92. In addition, a study conducted among glaucoma patients in a Turkish population, found
that the presence of depression was associated with lower QoL scores111. Furthermore, a study
that used the Hamilton Depression Rating Scale among Singaporean patients with glaucoma,
found that 30% of their study population had depression, and found that female sex and
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worsening clinical outcomes of the eye were significant factors associated with depression16.
Supporting our study findings, Wilson et al. (2002) reported that clinical outcome measures such
as visual acuity, visual field severity and use of topical medication were not strongly predictive
of depression among glaucoma patients182.

6.3.3 Vision-related Quality of Life
The third objective of our study was to assess vision-related quality of life (VRQoL) as measured
by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), and determine
which clinical and/or demographic variables impacted the composite score, in glaucoma suspects
and patients diagnosed with glaucoma.
The VRQoL of our study population was reported to be high, with a composite score of
88.7±12.4. As previously stated, there were only 15% of patients who were diagnosed with
severe glaucoma in our study population. In contrast, a study conducted among a Turkish
population, reported a lower composite score of (66.4±19.3)184. However, the mean age in the
Turkish population was younger (60.9±14.5 years) and only 9.8% were diagnosed with
glaucoma; the rest of the patients were diagnosed with either cataract (57.4%), diabetic
retinopathy (13.2%), age-related macular degeneration (11.4%) or degenerative myopia
(8.2%)184. Karadeniz et al. (2017) reported a composite score of 86.4±7.0 among glaucoma
patients and found significant correlation between BCVA and VRQoL185. Although, on average,
the age of the study population reported by Karadeniz et al. (2017) was younger (64.9±10.5
years) than the age of our study population, the composite score obtained in both study
populations were similar.
Previous studies have assessed the VRQoL of glaucoma patients using the NEI VFQ-25.
Carreras et al. (2017) found that patients with moderate to severe glaucoma reported significantly
lower NEI VFQ-25 scores than patients with normal eyes186. Cahill et al. (2005) reported that
NEI VFQ-25 scores, among a group of patients with low vision, were negatively correlated with
increasing age and duration of vision loss187. A study among a Swedish population used a
Swedish translation of the NEI VFQ-25 to assess VRQoL and concluded that the scores were
associated with clinical characteristics such as visual acuity and visual field loss and patients
with no visual impairment scored higher than patients with visual impairment188. Similarly, our
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results suggest that the best possible predictor variable of VRQoL was BCVA in the worseseeing eye. Specifically, the absolute values of the multivariable regression coefficients suggest
that legal blindness (b = -17.03) and moderate visual acuity loss (b = -8.20) are expected to have
a larger decrease on VRQoL, compared to patients with mild visual acuity loss. In addition,
Murata et al. (2015) confirm our results, as they also reported BCVA in the worse-eye as the
most important variable for VRQoL189. Takahashi et al. (2016) also found significant
associations between visual function impairment and VRQoL190. In addition, Sun et al. (2016)
reported that patients with visual defects in the better eye were more likely to have lower
VRQoL scores191. Thus, vision-specific clinical outcome measures are important predictor
variables of VRQoL.

6.3.4 Preference-based Health-Related Quality of Life
The fourth objective of our research study was to assess the preference-based HRQoL as
measured by the Time Trade-Off technique (TTO) and determine which clinical and/or
demographic variables impact the utility values in glaucoma suspects and patients diagnosed
with glaucoma.
Among our study population only about 10% had a low visual acuity with low vision reporting
either counting fingers (CF), hand motion (HM), light perception (LP) or no light perception
(NLP). Thus, very few patients reported low TTO utility values. Previous studies reported
associations between preference-based HRQoL and visual acuity. Brown (1999) concluded that
preference-based HRQoL decreases as the vision in the better-seeing eye decreases87. Brown et
al. (1999) reported that patients with a poor visual acuity value (i.e., counting fingers) were
willing to give up more years of their remaining life compared to patients with a better visual
acuity (i.e., 20/20)123.
Recall from Section 2.7.4 that utility values are rated on a scale between 0 (death) and 1 (perfect
health). The utility value reported by our patient population, on average was 0.91. About 71% of
the patients reported a perfect utility value of 1, meaning that majority of the patients were not
willing to give up any years of life for perfect vision. This finding may, in part, be due to the
relatively small number of severe glaucoma patients in the study population (15%). Likewise,
Jampel et al. (2002) reported a high preference-based HRQoL (utility value = 0.93) among
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patients diagnosed with glaucoma192. The glaucoma patients in Jampel et al.’s (2002) study were
similar in age to our study population (71.8±11.2 years) and majority were Caucasian (76%)192.
A low mean TTO utility value of 0.64 was reported among a group of Indian glaucoma patients,
representing a poorer preference-based HRQoL96. Another study among a Chinese population
reported a mean utility value of 0.88124. Since our study population was about 80% Caucasian,
further investigation would be interesting in a more diverse Canadian population to evaluate the
effect of race in a country which has access to a universal health care system.
Aspinall et al. (2008) reported that only 17% of the patients were willing to consider trading their
remaining years of life for perfect vision125. Among our study population, about 30% were
willing to consider trading their remaining years of life for perfect vision. Although Aspinall et
al. (2008) did not include patients with other ocular comorbidities and had a smaller sample size
(n = 72), similar to our research study, only a minority of patients were willing to trade their
years of life for perfect vision.
The results of our study found that the most promising predictor variables of preference-based
HRQoL were: age, education, use of mobility aids, BCVA in the worse-seeing eye, number of
comorbidities, number of ocular conditions, number of ocular procedures, glaucoma stage, time
since diagnosis and initial treatment. To avoid overfitting, the TTO model would benefit from
further assessment, with a larger population of diverse glaucoma severity groups.
Similar to our study findings, previous studies reported both clinical and demographic
associations with preference-based HRQoL. Like our study, Sharma et al. (2000) included
patients with various ocular conditions and determined that preference-based HRQoL was
significantly associated with only BCVA in the better-seeing eye138. Kobelt et al. (2006) reported
that clinical variables such as total visual acuity, visual acuity in the better-seeing eye were
significantly correlated with preference-based HRQoL and patients with severe damage reported
poorer HRQoL193. However, very few patients in our study population had severe glaucomatous
damage. In addition, to the commonly reported association between preference-based HRQoL
and visual acuity loss, Gupta et al. (2005) also found significant associations between
preference-based HRQoL and educational status96. Our study findings also found education to be
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predictive of preference-based HRQoL. Likewise, Guedes et al. (2014) reported that higher
education tended to predict higher preference-based HRQoL 150. Zhang et al. (2015) also
reported that preference-based HRQoL was related to education level and employment status151.
Contrary to our findings, Brown (1999) found that age, level of education, gender, race, length of
time of visual loss and number of comorbidities did not significantly affect preference-based
HRQoL87. Brown (1999) only included patients who had a visual loss of 20/40 or worse,
whereas in our study included patients with visual loss better than 20/40.
It is important to note that the mentioned studies only performed multivariable regression
analysis to determine which variables were associated with preference-based HRQoL, whereas
our research study performed multivariable regression analysis, stepwise regression by AIC and
variable selection using CART to identify the most promising predictor variables of preferencebased HRQoL.

6.3.5 Models for Predicting Patient-Reported Outcomes
The final objective of this study was to develop models for predicting social support and
community integration, presence of depressive symptoms, VRQoL and preference-based
HRQoL based on clinical and/or demographic variables, and validate the resulting models.
A total of 13 predictor variables were included in the initial model for analysis for each PRO.
After performing three model selection methods (multivariable regression, stepwise regression
by AIC, and CART) and assessing the model performance using LOOCV, the most promising
predictor variables to be included in the final model for each PRO were identified to be the
following:
Social support and community integration: age, sex, income, living arrangement and
use of mobility aids
Presence of depressive symptoms: use of mobility aids and initial treatment
Vision-related quality of life: BCVA in the worse-seeing eye
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Preference-based HRQoL: age, education, use of mobility aids, BCVA in the worseseeing eye, number of comorbidities, number of ocular conditions, number of ocular
procedures, glaucoma stage, time since diagnosis and initial treatment
Our study findings focus on the methodology used to identify the most promising predictor
variables of each outcome. Previous studies solely relied on multivariable regression to identify
significant variables and often conclusions from these research studies were based on
significance levels. In contrast, our research study presents a novel contribution to the
methodology using a combination of inferential statistics and machine learning techniques to
identify the best predictor variables of an outcome. Further, the accuracy of each model was
determined to provide stronger support for the conclusions. Future research can investigate how
to best apply and incorporate these study findings into clinical practice guidelines for better
glaucoma management. This would be a novel utilization of our research as currently very few
international clinical practice guidelines incorporate evidence on PROs194. We also determined
the accuracy of each model to provide more support for our conclusions.
The prediction models permit estimation of the patients’ social support and community
integration, depressive symptoms, VRQoL and preference-based HRQoL. This can be used to
allow ophthalmologists to identify which patients who are at high-risk for higher depressive
symptoms, lower social support and community integration, VRQoL and preference-based
HRQoL.

6.4

Study Strengths and Limitations

One of the strengths of this study is the sample size (n = 250), which was large compared to
previous studies assessing PROs among glaucoma patients. Another strength is that this study
included patients with various levels of glaucoma severity, who had a variety of glaucoma
interventions ranging from observation to surgery, and who had concurrent comorbidities. The
research also benefited from low levels of missing data, so multiple imputation only needed to be
performed on one variable. In addition, multiple reliable and valid PRO measurement tools were
employed. A comprehensive set of PROs, using specific measurement tools as opposed to
generic ones, allowed capture of precise, disease-specific results.
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Most of the patients in this study had mild glaucoma as defined by Canadian practice guidelines
which likely reflects the effectiveness of screening and early intervention in the community and
practice in which the study was done. Patients with severe glaucoma and those living in a
nursing or retirement home were under-represented in this population, which may have different
outcomes if compared to a more advanced disease population.
Although our study included several types of glaucoma and other ocular conditions, results may
differ if a subgroup analysis was performed, the latter which would benefit from an even larger
sample size than the one examined. Also, since we conducted an exploratory analysis, some of
the identified predictor variables may have associations simply by chance. Although this study
was unique in utilizing a number of PROs, each is limited by their nature of being subjective and
variable even among patients with similar clinical characteristics. Finally, we did not capture the
patient’s knowledge of glaucoma, which may present as a bias when measuring PROs.

6.5

Future Directions

This study presented proof of principle findings that provide a basis for future investigation. It
would be ideal to conduct future studies intended to identify predictor variables of PROs that
employ similar methodology using a combination of inferential statistics, machine learning
techniques and model assessment. Previous ophthalmic studies rely on multivariable regression
analysis for their analysis and interpret their results based on statistical significance. However,
results should be interpreted beyond statistical significance and assess how accurately a model
will perform. Machine learning techniques can provide a great contribution to ophthalmic
research and practice by identifying patients at high risk for poor PROs. Further research could
explore a broader range of demographic and clinical variables, and the role of other PROs among
glaucoma patients.
Based on the results for the preference-based HRQoL model, where 10 predictor variables were
identified, recommendations for future research would be to develop a more specific model to
identify fewer predictor variables. A multicentre study that would allow input from a diverse
population would be useful to confirm the association of the identified predictor variables in
other settings. It would also be informative to track temporal changes in PROs, through longer
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follow-up periods. Therefore, further studies with a larger diverse population stratified by disease
severity and longer follow-up periods would be required for validation the latter which, however,
would be limited by the challenges involved in performing long-term, multicentre studies.

6.6

Conclusion

As governments are now investing in programs aiming to increase patient input into health care
decision making, studies and methodologies such as this will have continued and increased
relevance. Measuring PROs is particularly useful for chronic, progressive diseases such as
glaucoma as their management and treatment have a greater impact on quality of life when
compared to acute and curable conditions. The importance has recently increased due to the
creation of formalized programs by governments which seek direct patient input into health care
decision making policies. Our research adds to the literature a novel methodology for
determining predictor variables for important PROs. Our findings highlight that, in the case of
glaucoma, PROs are mostly influenced by demographic characteristics, rather than clinical
characteristics.
The study results support the potential of developing a clinical tool that may allow clinicians to
identify patients who may benefit from additional support and resources, beyond routine clinical
care and treatment. Comprehensive and targeted rehabilitative services can be developed to
target the needs of these patients. Studies such as this may be useful to health care policy makers
when making decisions on how to best allocate resources directed to patient-centered approaches
to health care. Although, inherently subjective, patient input into their health care has become a
priority for a number of countries, including Canada. As this is a relatively recent initiative,
evidence to guide this process would help ensure the most cost-effective implementation of such
programs. In the case of glaucoma, it would be important to stress the context, which requires
research across various ophthalmic practice settings. For instance, patient’s experience can be
influenced by wait times, the type and location of the health care facility, relationship with the
ophthalmologist and administrative staff, access to innovations in care, etc. Among our study
population, the PROs were found to be high, revealing that patients were satisfied with the
quality of care. Many of the patients expressed their trust in the ophthalmologist, so that they did
not have to stress about their glaucoma progression. Since the patients in our study were only
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recruited from one practice, our results may only be generalizable to patients of this
ophthalmologist, her referral base and the setting in which she practices. Patients with severe
glaucoma, as well as non-Caucasian patients, were under-represented in this study; thus, these
results may not be generalizable to other populations and settings.
The predictive performance of each model is specific to our study population, and would need
further validation among a diverse population to be generalizable. This would further elucidate
the practical value of each model. Although we cannot be certain of the exact relationship
between the predictor variables and each PRO, the methodology in this study provides a solid
foundation upon which further studies can be done. This happens to coincide at a time in which
patient-driven health care has become a priority for a number of provincial and international
governments.
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Appendix B: Sample size calculation formulas
1. Beta function:
J

n %, # =

6 J;+ (1 − 6)o;+ i6

)

where B is the normalization constant
% and # are real numbers
2. Cohen’s f2 effect size for an F-test:
Y,
j =
1 − Y,
,

where Y, is the squared multiple correlation
3. Error function:
_Rj % =
where

,

p

2

p

J

q

_ ;p i6

)

is the normalization factor, defined as the probability density function

4. F-distribution cumulative distribution function:
r %; i+ , i, = =

tu J (
tu Jvtq

i+ i,
, )
2 2

where i+ and i, are the degrees of freedom
= is the regularized lower incomplete beta function (

w(J;x,y)
w(x,y)

)

5. Non-central F-distribution cumulative distribution function:
¥

r % i+ , i, , l =
1G)

1
( l)1 ;l
i+ r
i+
i,
( 2
)_ , =(
| + z, )
z!
i, + i+ r 2
2

where i+ and i, are the numerator and denominator degrees of freedom

l is the non-central parameter
F is the Fisher F-value
I is the regularized lower incomplete beta function (
6. Non-central F-distribution parameter:

l = j ,I

w(J;x,y)
w(x,y)

)
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where j , is the effect size
I is the sample size
7. Normal distribution cumulative distribution function:
1
%−}
r %; µ, | , = [1 + _Rj (
)]
2
| 2
where µ is the mean
| is the standard deviation
_Rj is the error function
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Appendix C. Community Integration Questionnaire (CIQ)
1. Who usually does the shopping for groceries or
other necessities in your household?
2. Who usually prepares meals in your household?

3. In your home who usually does the everyday
housework?

4. Who usually cares for the children in your home?

5. Who usually plans social arrangements such as
get-togethers with family and friends?
6. Who usually looks after your personal finances,
such as banking or paying bills
7. Approximately how many times a month do you
usually participate in shopping outside your
home?
8. Approximately how many times a month do you
usually participate in leisure activities such as
movies, sports, restaurants etc.
9. Approximately how many times a month do you
usually visit your friends or relatives?
10. When you participate in leisure activities do you
usually do this alone or with others?

11. Do you have a best friend with whom you
confide?
12. How often do you travel outside the home?

o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o
o

Yourself alone
Yourself and someone else
Someone else
Yourself alone
Yourself and someone else
Someone else
Yourself alone
Yourself and someone else
Someone else
Not applicable
Yourself alone
Yourself and someone else
Someone else
Not applicable
Yourself alone
Yourself and someone else
Someone else
Yourself alone
Yourself and someone else
Someone else
Never
1-4 times
5 or more
Never
1-4 times
5 or more
Never
1-4 times
5 or more
Mostly alone
Mostly with friends
Mostly with family members
With a combination of family
and friends
Yes
No
Almost every day
Almost every week
Seldom/never (less than once
per week)
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13. Please choose the answer that best corresponds to
your current (during the past month) work
situation:

14. Please choose the answer that best corresponds to
your current (during the past month) school or
training program situation:

15. In the past month, how often did you engage in
volunteer activities

o Full-time (more than 20
hours/week)
o Part-time (less than or equal
to 20 hours/week)
o Not working, but actively
looking for work
o Not working, not looking for
work
o Not applicable (retired,
disability)
o Full-time
o Part-time
o Not attending school, or
training program
o Not applicable (retired,
disability)
o Never
o 1-4 times
o 5 or more

*(adapted from: Dijkers, M. (2000). The Community Integration Questionnaire. The Center for
Outcome Measurement in Brain Injury. http://www.tbims.org/combi/ciq)
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Appendix D. Patient Health Questionnaire (PHQ-9)

Over the last 2 weeks, how often have you been
bothered by any of the following problems?

Not at
all

Several More than
Days half the days

Nearly
Every
day

1. Little interest or pleasure in doing things

0

1

2

3

2. Feeling down, depressed, or hopeless

0

1

2

3

3. Trouble falling asleep or sleeping too much

0

1

2

3

4. Feeling tired or having little energy

0

1

2

3

5. Poor appetite or overeating

0

1

2

3

6. Feeling bad about yourself- or that you are
a failure or have let yourself or family down

0

1

2

3

7. Trouble concentrating on things, such as reading
the newspaper or watching television

0

1

2

3

8. Moving or speaking so slowly that other people
could have noticed. Or the opposite-being so fidgety
or restless that you have been moving around a lot
more than usual

0

1

2

3

9. Thoughts that you would be better off dead, or of
hurting yourself in some way

0

1

2

3

Add Columns

+

+
Total
If you checked off any problems, how difficult have these problems made it for you to do your
work, take care of the things at home, or get along with other people?
Not difficult
Somewhat
Very
Extremely
at all
difficult
difficult
difficult

* Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with
an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or
distribute

138

Appendix E. National Eye Institute Visual Function Questionnaire – 25 (NEI
VFQ-25)
PART 1 - GENERAL HEALTH AND VISION
1. In general, would you say your overall health is: (Circle One)
Excellent............................... 1
Very Good............................ 2
Good...................................... 3
Fair......................................... 4
Poor........................................ 5
2. At the present time, would you say your eyesight using both eyes (with glasses or contact
lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?
(Circle One)
Excellent............................... 1
Good...................................... 2
Fair......................................... 3
Poor........................................ 4
Very Poor.............................. 5
Completely Blind................ 6
3. How much of the time do you worry about your eyesight? (Circle One)
None of the time............................. 1
A little of the time........................... 2
Some of the time............................ 3
Most of the time.............................. 4
All of the time?................................ 5
4. How much pain or discomfort have you had in and around your eyes
(for example, burning, itching, or aching)? Would you say it is: (Circle One)
None....................................... 1
Mild......................................... 2
Moderate............................... 3
Severe, or............................. 4
Very severe?........................ 5
PART 2 - DIFFICULTY WITH ACTIVITIES
The next questions are about how much difficulty, if any, you have doing certain activities
wearing your glasses or contact lenses if you use them for that activity.
5. How much difficulty do you have reading ordinary print in newspapers? Would you say you
have: (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
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Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested
in doing this...................................... 6
6. How much difficulty do you have doing work or hobbies that require you to see well up close,
such as cooking, sewing, fixing things around the house, or using hand tools? Would you say:
(Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
7. Because of your eyesight, how much difficulty do you have finding something on a crowded
shelf? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
8. How much difficulty do you have reading street signs or the names of stores?(Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this........................... 6
9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or curbs
in dim light or at night? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
10. Because of your eyesight, how much difficulty do you have noticing objects off to the side
while you are walking along?(Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
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Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
11. Because of your eyesight, how much difficulty do you have seeing how people react to things
you say? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
12. Because of your eyesight, how much difficulty do you have picking out and matching your
own clothes? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
13. Because of your eyesight, how much difficulty do you have visiting with people in their
homes, at parties, or in restaurants? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
14. Because of your eyesight, how much difficulty do you have going out to see movies, plays,
or sports events? (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
15. Are you currently driving, at least once in a while? (Circle One)
Yes........................ 1 Skip To Q 15c
No ......................... 2
15a. IF NO: Have you never driven a car or have you given up driving? (Circle One)
Never drove........ 1 Skip To Part 3, Q 17
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Gave up............... 2
15b. IF YOU GAVE UP DRIVING: Was that mainly because of your eyesight, mainly for some
other reason, or because of both your eyesight and other reasons? (Circle One)
Mainly eyesight..................................... 1 Skip To Part 3, Q 17
Mainly other reasons ........................... 2 Skip To Part 3, Q 17
Both eyesight and other reasons .... 3 Skip To Part 3, Q 17
15c. IF CURRENTLY DRIVING: How much difficulty do you have driving during the daytime
in familiar places? Would you say you have: (Circle One)
No difficulty at all................................. 1
A little difficulty..................................... 2
Moderate difficulty............................... 3
Extreme difficulty................................. 4
16. How much difficulty do you have driving at night? Would you say you have: (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
16A. How much difficulty do you have driving in difficult conditions, such as in bad weather,
during rush hour, on the freeway, or in city traffic? Would you say you have: (Circle One)
No difficulty at all......................................................... 1
A little difficulty............................................................. 2
Moderate difficulty....................................................... 3
Extreme difficulty......................................................... 4
Stopped doing this because of your eyesight..... 5
Stopped doing this for other reasons or not interested in doing this............. 6
PART 3: RESPONSES TO VISION PROBLEMS
The next questions are about how things you do may be affected by your vision. For each one,
please circle the number to indicate whether for you the statement is true for you all, most, some,
a little, or none of the time. (Circle One On Each Line)
All of
Most of
Some
A little
None of
the time the time of the time
of the time the time
17 Do you accomplish less
than you would like
1
2
3
4
5
because of your vision?
18 Are you limited in how
long you can work or do
1
2
3
4
5
other activities because
of your vision?
19 How much does pain or
1
2
3
4
5
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discomfort in or around
your eyes, for example,
burning, itching, or
aching, keep you from
doing what you’d like to
be doing?
For each of the following statements, please circle the number to indicate whether for you the
statement is definitely true, mostly true, mostly false, or definitely false for you or you are not
sure. (Circle One On Each Line)
Definitely Mostly
Not
Mostly Definitely
true
true
sure
false
false
20 I stay home most of the time
1
2
3
4
5
because of my eyesight.
21 I feel frustrated a lot of the
1
2
3
4
5
time because of my eyesight.
22 I have much less control over
what I do, because of my
1
2
3
4
5
eyesight.
23 Because of my eyesight, I
have to rely too much on
1
2
3
4
5
what other people tell me
24 I need a lot of help from others
1
2
3
4
5
because of my eyesight.
25 I worry about doing things that
will embarrass myself or others,
1
2
3
4
5
because of my eyesight.
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Appendix F. Time Trade-Off (TTO)
How many years do you expect to live? __________________years
Suppose there was a new technology that could restore your eyesight to perfectly normal in
both eyes. The technology always works but decreases the length of time you live.
What is the maximum number of years, if any, that you would be willing to give up if you
could receive this technology and have perfect vision for your remaining years?
___________________years
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